NOMAD Power Solutions posts $167M nine-month loss
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
NOMAD Power Solutions, Inc. completed a reverse acquisition on July 1, 2026, with NOMAD Transportable Power Systems as accounting acquirer; transportable power is now the company’s primary business. Legacy Lixte’s oncology and proton-therapy operations are included only from July 1. Conversion of Series D preferred shares into 50,366,070 common shares remains subject to Nasdaq approval of the new listing application and stockholder approval and had not occurred as of this report. Management intends to evaluate a disposition of the legacy life-sciences portfolio.
For the nine months ended September 30, 2026, sales were $1.093 million and net loss was $167.314 million, including $147.1 million of non-cash warrant charges and $6.4 million of merger-related costs. Net cash used in operating activities was $8.297 million. At September 30, cash was $5.649 million and the working-capital deficit was $4.765 million. A $6.57 million secured note issued September 28 produced $5.64 million in net proceeds and bears 9% annual interest.
Management said these conditions raise substantial doubt about the company’s ability to continue as a going concern within one year after the financial statements are issued.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- None.
Negative
- Major pointGoing-concern warning cites a $167.314 million net loss and $4.765 million deficit.
- Minor point$147.1 million of non-cash warrant charges were included in nine-month results.
Filing Explained
After six months, the secured note lets its lender demand monthly cash redemptions and requires prepayment of up to one quarter of financing proceeds.
This quarterly report covers the period ended
At the acquisition, former NOMAD stockholders held about
The
Key Figures
Key Terms
reverse acquisition technical
substantial doubt financial
secured promissory note financial
non-cash warrant charges financial
Series D Non-Voting Convertible Preferred Stock financial
embedded derivative features financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What caused NMAD’s $167.314 million net loss for the first nine months of 2026?
What are the repayment terms of NMAD’s Streeterville note?
When can NMAD’s Series D preferred stock convert into common shares?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the quarterly period ended
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission
file number:
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of | (I.R.S. Employer | |
| incorporation or organization) | Identification Number) |
(Address of principal executive offices, including Zip Code)
(Registrant’s telephone number, including area code)
Lixte Biotechnology Holdings, Inc.
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ |
| Smaller
reporting company | |
| Emerging
growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes
☐ No
As
of October 30, 2026, the Company had
EXPLANATORY NOTE
This Quarterly Report covers the three and nine months ended September 30, 2026. The merger of Lixte Biotechnology Holdings, Inc. and NOMAD Transportable Power Systems, Inc. closed on July 1, 2026 and is accounted for as a reverse acquisition, with NOMAD as the accounting acquirer. Accordingly, results for all periods before July 1, 2026, including the first six months of 2026 and all 2025 comparative periods, are those of NOMAD Transportable Power Systems, Inc. as a private company before the merger closed. Legacy Lixte operations (the LB-100 program and the LiGHT proton therapy system) are included only from July 1, 2026. The nine months ended September 30, 2026 include $147.1 million of non-cash warrant charges and $6.4 million of merger-related transaction costs recorded in connection with the merger.
The conversion into common stock of the Series D Non-Voting Convertible Preferred Stock issued in the merger remains subject to Nasdaq approval of the Company’s new listing application and to stockholder approval, and had not occurred as of the date of this report.
NOMAD POWER SOLUTIONS, INC. AND SUBSIDIARIES
(formerly Lixte Biotechnology Holdings, Inc.)
TABLE OF CONTENTS
Page Number | |
| PART I - FINANCIAL INFORMATION | 3 |
| Item 1. Condensed Consolidated Financial Statements | 3 |
| Condensed Consolidated Balance Sheets – September 30, 2026 (Unaudited) and December 31, 2025 | 3 |
| Condensed Consolidated Statements of Operations (Unaudited) – Three and Nine Months Ended September 30, 2026 and 2025 | 4 |
| Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) – Three and Nine Months Ended September 30, 2026 and 2025 | 5 |
| Condensed Consolidated Statements of Cash Flows (Unaudited) – Nine Months Ended September 30, 2026 and 2025 | 8 |
| Notes to Condensed Consolidated Financial Statements (Unaudited) – Three and Nine Months Ended September 30, 2026 and 2025 | 9 |
| Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 38 |
| Item 3. Quantitative and Qualitative Disclosures About Market Risk | 46 |
| Item 4. Controls and Procedures | 46 |
| PART II - OTHER INFORMATION | 47 |
| Item 1. Legal Proceedings | 47 |
| Item 1A. Risk Factors | 47 |
| Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | 47 |
| Item 3. Defaults Upon Senior Securities | 47 |
| Item 4. Mine Safety Disclosures | 47 |
| Item 5. Other Information | 47 |
| Item 6. Exhibits | 48 |
| SIGNATURES | 49 |
| i |
Forward Looking Statements
This report contains statements about future developments, including our expected liquidity, financing plans, product demand, production capacity, commercial deployments, clinical programs and potential portfolio transactions. These statements reflect current expectations and are subject to uncertainty. Actual outcomes may differ because of customer acceptance and delivery timing, supply constraints, financing availability, debt terms, clinical and regulatory developments, and the other risks described in this report and our SEC filings. Statements about grants and future orders do not assure receipt of funding or revenue. Forward-looking statements speak as of the date of this report. We undertake no obligation to update them except as required by law.
| ii |
PART I - FINANCIAL INFORMATION
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOMAD POWER SOLUTIONS, INC. AND SUBSIDIARIES
(formerly Lixte Biotechnology Holdings, Inc.)
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except share amounts)
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash | $ | $ | ||||||
| Accounts receivable | ||||||||
| Employee tax withholding receivable | - | |||||||
| Inventory, net | ||||||||
| Deposits for inventory | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Revenue-generating equipment, net | ||||||||
| Property and equipment, net | ||||||||
| LiGHT proton therapy system equipment | - | |||||||
| Operating lease right-of-use assets | ||||||||
| Goodwill | - | |||||||
| Intangible assets, net | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable (including $ | ||||||||
| Accrued expenses (including $ | ||||||||
| Payroll taxes | - | |||||||
| Transition agreement with related party | ||||||||
| Research and development contract liabilities | - | |||||||
| Customer deposit | - | |||||||
| Deferred revenue | ||||||||
| Deferred grant revenue | ||||||||
| Operating lease liabilities, current | ||||||||
| Debt, current, net of discount (including $ | ||||||||
| Total current liabilities | ||||||||
| Operating lease liabilities, long-term | ||||||||
| Debt, long term | - | |||||||
| Total liabilities | ||||||||
| Commitments and Contingencies | - | - | ||||||
| Stockholders’ Equity (Deficit): | ||||||||
| Convertible Preferred Stock, $ | - | - | ||||||
| Common stock, $ | - | |||||||
| Additional paid-in capital | ||||||||
| Common shares issuable – | ||||||||
| Exercise-price receivable | ( | ) | - | |||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total NOMAD Power Solutions stockholders’ equity (deficit) | ( | ) | ||||||
| Non-controlling interest | - | |||||||
| Total stockholders’ equity (deficit) | ( | ) | ||||||
| Total liabilities and stockholders’ equity | $ | $ | ||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
| 3 |
NOMAD POWER SOLUTIONS, INC. AND SUBSIDIARIES
(formerly Lixte Biotechnology Holdings, Inc.)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except share and per share amounts)
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Sales | $ | $ | $ | $ | ||||||||||||
| Cost of goods sold | ||||||||||||||||
| Gross profit | ||||||||||||||||
| Costs and expenses: | ||||||||||||||||
| General and administrative costs | ||||||||||||||||
| Research and development costs | ||||||||||||||||
| Transaction costs | - | - | ||||||||||||||
| Total costs and expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income (expenses): | ||||||||||||||||
| Interest income | ||||||||||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Loss on debt extinguishment | ( | ) | - | ( | ) | - | ||||||||||
| Loss (gain) on issuance of warrant liability | - | ( | ) | - | ||||||||||||
| Change in fair value of warrant liability | - | - | ( | ) | - | |||||||||||
| Net loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Non-controlling interest | - | - | ||||||||||||||
| Net loss attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Net loss per common share – basic and diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average common shares outstanding – basic and diluted | ||||||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
| 4 |
NOMAD POWER SOLUTIONS, INC. AND SUBSIDIARIES
(formerly Lixte Biotechnology Holdings, Inc.)
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)
(Amounts in thousands, except share amounts)
For the Three Months Ended September 30, 2026
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Receivable | Deficit | interest | Equity | ||||||||||||||||||||||||||||||||||
Series D Preferred Stock | Common Stock Issuable | Common Stock | Additional Paid in | Exercise Price | Accumulated | Non- controlling | Total Stockholders’ | |||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Receivable | Deficit | interest | Equity | ||||||||||||||||||||||||||||||||||
| Balance, June 30, 2026, as adjusted for recapitalization (Note 1) | $ | - | - | $ | - | $ | $ | $ | - | $ | ( | ) | $ | - | $ | ( | ) | |||||||||||||||||||||||||||
| Common shares issued on reverse acquisition | - | - | ||||||||||||||||||||||||||||||||||||||||||
| Shareholders distribution on reverse acquisition | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||||
| Fair value of vested stock options | - | |||||||||||||||||||||||||||||||||||||||||||
| Common shares issued on vesting of restricted stock units | - | - | ||||||||||||||||||||||||||||||||||||||||||
| Common shares forfeited for employee taxes on restricted stock units | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||
| Common shares issued for services | - | - | ||||||||||||||||||||||||||||||||||||||||||
| Common shares issued for warrant liability | - | - | ||||||||||||||||||||||||||||||||||||||||||
| Common shares issued on exercise of options pending receipt of exercise price | - | - | ( | ) | - | |||||||||||||||||||||||||||||||||||||||
| Common shares issued on exercise of warrants pending receipt of exercise price | - | - | ( | ) | - | |||||||||||||||||||||||||||||||||||||||
| Issuance of liability-classified warrants | (1,500 | ) | (1,500 | ) | ||||||||||||||||||||||||||||||||||||||||
| Common shares issued on exercise of pre-funded warrants | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||
| Common shares issued on exercise of warrants for cash | - | |||||||||||||||||||||||||||||||||||||||||||
| Common shares issued on exercise of options for cash | - | - | ||||||||||||||||||||||||||||||||||||||||||
| Purchase of fundamental transaction warrants | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||
| Net loss | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||||||||
| Balance, September 30, 2026 | $ | - | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | |||||||||||||||||||||||||||||||
| 5 |
For the Nine Months Ended September 30, 2026
Series D Preferred Stock | Common Stock Issuable | Common Stock | Additional Paid in | Exercise Price | Accumulated | Non- controlling | Total Stockholders’ | |||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Receivable | Deficit | interest | Equity | ||||||||||||||||||||||||||||||||||
| Balance, December 31, 2025, as adjusted for recapitalization (Note 1) | $ | - | $ | $ | | $ | $ | - | $ | ( | ) | $ | - | $ | ( | ) | ||||||||||||||||||||||||||||
| Common shares issued on reverse acquisition | - | - | ||||||||||||||||||||||||||||||||||||||||||
| Shareholders distribution on reverse acquisition | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||||
| Fair value of vested stock options | - | |||||||||||||||||||||||||||||||||||||||||||
| Common shares issued on settlement of trade accounts payable | - | - | ||||||||||||||||||||||||||||||||||||||||||
| Common shares issued on vesting of restricted stock units | - | - | ||||||||||||||||||||||||||||||||||||||||||
| Common shares forfeited for employee taxes on restricted stock units | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||
| Common shares issued for services | - | ( | ) | ( | ) | - | ||||||||||||||||||||||||||||||||||||||
| Common shares issued for financing costs | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||
| Shares issued on exercise of liability-classified warrants | - | - | ||||||||||||||||||||||||||||||||||||||||||
| Common shares issued on exercise of options pending receipt of exercise price | - | ( |
) | - | ||||||||||||||||||||||||||||||||||||||||
| Common shares issued on exercise of warrants pending receipt of exercise price | - | ( |
) | - | ||||||||||||||||||||||||||||||||||||||||
| Common shares issued on exercise of pre-funded warrants | - | - | - | |||||||||||||||||||||||||||||||||||||||||
| Common shares issued on exercise of warrants for cash | - | |||||||||||||||||||||||||||||||||||||||||||
| Common shares issued on exercise of options for cash | - | - | ||||||||||||||||||||||||||||||||||||||||||
| Purchase of fundamental transaction warrants | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||
| Net loss | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||||||||
| Balance, September 30, 2026 | $ | - | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | |||||||||||||||||||||||||||||||
| 6 |
For the Three Months Ended September 30, 2025
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||||||||||||||
| Series D Preferred Stock |
Common Stock | Common Stock Issuable | Additional Paid in | Accumulated | Total Stockholders’ |
|||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||||||||||||||
| Balance, June 30, 2025 | $ | - | $ | $ | $ | ( | ) | $ | ( |
) | ||||||||||||||||||||||||||
| Fair value of vested stock options | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||
| Common shares issued on vesting of restricted stock units | - | - | - | |||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | ( | ) | ( |
) | |||||||||||||||||||||||||
| Balance, September 30, 2025 | $ | - | $ | $ | $ | ( | ) | $ | ( |
) | ||||||||||||||||||||||||||
For the Nine Months Ended September 30, 2025
| Series D Preferred Stock |
Common Stock | Common Stock Issuable | Additional Paid in | Accumulated | Total Stockholders’ | |||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||||||||||||||
| Balance, December 31, 2024 | - | $ | - | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||
| Balance | $ | - | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Fair value of vested stock options | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||
| Common shares issued for employee compensation | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Common shares issued on vesting of restricted stock units | - | - | - | - | ||||||||||||||||||||||||||||||||
| Common stock issued for financing fees | - | - | - | |||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||
| Balance, September 30, 2025 | - | $ | - | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||
| Balance | $ | - | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
See accompanying notes to condensed consolidated financial statements.
| 7 |
NOMAD POWER SOLUTIONS, INC. AND SUBSIDIARIES
(formerly Lixte Biotechnology Holdings, Inc.)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(Amounts in thousands)
| 2026 | 2025 | |||||||
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation on property and equipment | ||||||||
| Depreciation on revenue-generating equipment | ||||||||
| Amortization of right-of-use assets | ||||||||
| Amortization of intangible assets | - | |||||||
| Amortization of debt discount | ||||||||
| Fair value of vested stock options | ||||||||
| Fair value of vested restricted stock units | ||||||||
| Fair value of common stock issued for services | - | |||||||
| Fair value of common stock issued for employee compensation | - | |||||||
| Loss on debt extinguishment | - | |||||||
| Loss on issuance of warrant liability | - | |||||||
| Change in fair value of warrant liability | - | |||||||
| Accrued interest | ( | ) | ( | ) | ||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | ( | ) | ||||||
| Inventories | ||||||||
| Deposits for inventory | ( | ) | ||||||
| Prepaid expenses and other current assets | ( | ) | ( | ) | ||||
| Accounts payable | ( | ) | ( | ) | ||||
| Accrued expenses | ( | ) | ||||||
| Payroll tax liability | - | |||||||
| Transition agreement for former related party | ( | ) | ( | ) | ||||
| Research and development contract liabilities | - | |||||||
| Customer deposits | - | |||||||
| Deferred revenue | ||||||||
| Deferred grant revenue | ( | ) | - | |||||
| Operating lease liabilities | ( | ) | ( | ) | ||||
| Net cash provided by (used in) operating activities | ( | ) | ||||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Cash received on reverse acquisition | - | |||||||
| Capitalized costs LiGHT proton therapy system equipment | ( | ) | - | |||||
| Intangible assets costs | ( | ) | ( | ) | ||||
| Purchase of property and equipment | ( | ) | - | |||||
| Net cash provided by (used in) investing activities | ( | ) | ||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from issuance of liability-classified warrants | - | |||||||
| Proceeds from exercise of stock options | - | |||||||
| Proceeds from exercise of warrants | - | |||||||
| Shareholders distribution on reverse acquisition | ( | ) | - | |||||
| Repurchase of fundamental transaction warrants | ( | ) | - | |||||
| Proceeds from debt, net of fees | ||||||||
| Repayment of debt | ( | ) | ( | ) | ||||
| Net cash provided by (used in) financing activities | ( | ) | ||||||
| NET CHANGE IN CASH | ||||||||
| Net increase (decrease) | $ | $ | ( | ) | ||||
| Cash - Beginning of period | ||||||||
| Cash - End of period | $ | $ | ||||||
| Supplemental disclosures of cash flow information: | ||||||||
| Cash paid for interest | $ | $ | ||||||
| Non-cash investing and financing activities: | ||||||||
| Common shares issued for loan fees | $ | - | $ | |||||
| Common shares issued for trade accounts payable | $ | $ | - | |||||
| Prepaid expenses from acquisition | $ | $ | - | |||||
| Note settled in acquisition | $ | $ | - | |||||
| LiGHT proton therapy system equipment from acquisition | $ | $ | - | |||||
| Right-to-use asset, net from acquisition | $ | $ | - | |||||
| Accounts payable from acquisition | $ | $ | - | |||||
| Research and development contract liabilities from acquisition | $ | $ | - | |||||
| Lease liabilities from acquisition | $ | $ | - | |||||
| Reverse acquisition equity issued | $ | $ | - | |||||
| Shares issued on exercise of liability-classified warrants | $ | $ | - | |||||
| Issuance of common stock issued for common stock issuable | $ | $ | - | |||||
| Payroll tax receivable and taxes payable | $ | $ | - | |||||
| Exercise price receivable | $ | $ | - | |||||
See accompanying notes to condensed consolidated financial statements.
| 8 |
NOMAD POWER SOLUTIONS, INC. AND SUBSIDIARIES
(formerly Lixte Biotechnology Holdings, Inc.)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Three and Nine Months Ended September 30, 2026 and 2025
(Unaudited. Dollars in thousands, except share and per-share amounts, unless expressly stated otherwise)
1. Organization and Basis of Presentation
NOMAD Power Solutions, Inc. is a Delaware holding company. Its business includes transportable battery energy storage systems, oncology drug development, and the development of proton therapy technology. The Company’s common stock trades on Nasdaq under NMAD.
On July 1, 2026, Lixte Biotechnology Holdings, Inc. (“Lixte”) completed the merger with Nomad Transportable Power Systems, Inc. (“NOMAD”). NOMAD was a private company that provided deployable, utility-grade battery energy storage systems. The transaction is accounted for as a reverse acquisition in which NOMAD is the accounting acquirer and Lixte is the accounting acquiree. The business conducted by NOMAD became the primary business conducted by Lixte. Upon closing of the acquisition on July 1, 2026, the Company was renamed Nomad Power Solutions, Inc., effective July 3, 2026, and began trading on the Nasdaq Stock Market under a new ticker symbol on July 6, 2026. As used herein, “Lixte” refers to the Company as it existed prior to the merger, and the “Company” refers to the consolidated accounts of Lixte and its wholly owned subsidiary NOMAD after the merger.
The accompanying financial statements are a continuation of NOMAD’s financial statements, presented under the legal parent’s name. They include NOMAD’s historical assets, liabilities and operating results and the acquired businesses beginning on the acquisition date. Comparative financial information reflects NOMAD, with its pre-acquisition equity structure adjusted to the legal parent’s equity structure under the merger exchange terms. Intercompany balances and transactions are eliminated.
The interim financial statements have been prepared under U.S. GAAP applicable to interim reporting and the SEC’s Form 10-Q and Regulation S-X requirements. They omit certain information required in annual financial statements. Management believes that all adjustments necessary for fair presentation have been included; these consist of normal recurring adjustments and separately identify other adjustments, if any. Interim results do not necessarily indicate full-year results. These statements should be read with NOMAD’s audited 2025 and 2024 financial statements filed as Exhibit 99.1 to the Company’s September 17, 2026 Form 8-K/A.
Business
The Company conducts its transportable power business through its wholly-owned subsidiary, NOMAD. In addition to its power infrastructure business, the Company advances a life-sciences portfolio. The Company has indicated an intent to evaluate a disposition of its legacy life-sciences portfolio as it focuses on its transportable power business; the status and terms of any such disposition have not yet been determined.
The Company’s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company does not have positive cash flows from operations, relies on stock-based compensation for a substantial portion of employee and consultant compensation, and is dependent on periodic infusions of equity capital to fund its operating requirements.
| 9 |
Going Concern
The
accompanying financial statements have been prepared under the assumption that the Company will continue as a going concern. In
accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”)
205-40, Going Concern, the Company’s management has evaluated whether there are conditions or events that raise
substantial doubt about its ability to continue as a going concern within one year after the date the accompanying financial
statements were issued. For the nine months ended September 30, 2026, the Company incurred a net loss of $
The Company’s ability to continue as a going concern depends on its ability to raise additional debt or equity capital to fund its business activities and ultimately achieve sustainable operating revenues and profitability. The Company has financed its working capital requirements through borrowings from various sources and the sale of its equity securities.
Because market conditions create uncertainty about the Company’s ability to secure additional funds, there can be no assurance that the Company will be able to secure additional financing on acceptable terms, as and when necessary to continue operations. If the Company is unable to obtain the cash resources necessary to satisfy the Company’s ongoing cash requirements, the Company could be required to scale back its business activities or to discontinue its operations entirely.
2. Summary of Significant Accounting Policies
Basis of Presentation
This summary of significant accounting policies is presented to assist in understanding the financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These financial statements and related notes are presented in accordance with generally accepted accounting principles in the United States of America (GAAP).
Use of Estimates
The preparation of financial statements in accordance with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the dates of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant areas requiring the use of management assumptions and estimates relate to stock-based compensation, including the fair value of common stock and share purchase warrants, as further described below. Macroeconomic factors, including but not limited to geopolitical issues between the U.S. and China, may create volatility, uncertainty, and economic disruption to the Company’s supply chain. Management has considered the impact of macroeconomic factors on its estimates, where relevant, in the preparation of the financial statements. Actual results could differ from these estimates and assumptions and could have a material effect on the Company’s reported financial position and results of operations.
Principles of Consolidation
The
accompanying consolidated financial statements include the accounts of NOMAD Power Solutions, Inc., its wholly-owned subsidiary NOMAD
Transportable Power Systems, Inc., Lixte Biotechnology, Inc., and its
Cash
Cash is held in deposit programs maintained at financial institutions in the United States and the United Kingdom. The Company’s policy is to maintain its cash balances with financial institutions with high credit ratings and in accounts insured by the Federal Deposit Insurance Corporation (“FDIC”) and/or the Securities Investor Protection Corporation (“SIPC”). The Company periodically maintains cash balances in excess of FDIC and SIPC insurance limits. The Company has not experienced any losses to date resulting from this policy.
| 10 |
Asset Acquisitions
The Company assesses whether an acquisition is a business combination or an asset acquisition. If substantially all of the gross assets acquired are concentrated in a single asset or group of similar assets, then the acquisition is accounted for as an asset acquisition, where the purchase consideration is allocated on a relative fair value basis to the assets acquired. An asset acquisition does not result in the recognition of goodwill and transaction costs are capitalized as part of the cost of the asset or group of assets acquired. The Company uses its best estimates and assumptions to assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. The acquisition costs are allocated to the assets acquired on a relative fair value basis.
Accounts Receivable
The Company records trade accounts receivable at the amounts billed to customers and presents them on the balance sheet, net of any allowance for estimated credit losses, if required. Management determines the allowance based on a variety of factors, including the age of the receivables, current economic conditions, historical losses, and other information management obtains regarding customers’ financial condition. The Company charges off receivables when they are deemed uncollectible. As of September 30, 2026 and December 31, 2025, the Company determined that no allowance for credit losses were needed.
Inventories
Inventories consist of equipment on hand that is available for sale. Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. Adjustments, if required, reduce inventory to its net realizable value, reflecting estimated excess, obsolescence, or impairment balances. Factors influencing these adjustments include changes in customer demand, rapid technological changes, and merchant bankruptcy. As of September 30, 2026 and December 31, 2025, the Company recorded no reserve for slow-moving inventory.
The Company regularly reviews the cost of inventories against their estimated net realizable value and records write-downs if any Work-in-Progress or Finished inventories have costs in excess of their net realizable values.
Deposits for Inventory
The Company utilizes multiple vendors and manufacturers to produce its mobile energy storage systems. At times, prepayments are required to begin production of critical elements in the systems. These prepayments are recorded as deposits for inventory and are moved to inventory or work in progress when the Company takes possession of the items as applicable. Deposits for inventory are stated at cost. Based on current demand for the Company’s mobile energy storage systems, these systems are expected to be sold at a profit once completed.
Property and Equipment
Property
and equipment are stated at cost, which includes the acquisition price and any direct costs to bring the asset into use at its
intended location, less accumulated depreciation. Depreciation is computed using the straight-line method over the assets’
estimated useful lives. The useful lives for depreciation purposes range from
Upon disposal of assets, the cost of the assets and the related accumulated depreciation are removed from the accounts, and gains or losses are reflected in the accompanying condensed statements of operations for the respective period.
| 11 |
Revenue Generating Equipment
Revenue-generating
equipment is stated at cost, which includes the acquisition price and any direct costs to bring the asset into use at its intended location,
less accumulated depreciation. Depreciation is computed using either the straight-line method over the assets’ estimated useful
lives or the units-of-production method based on the expected utilization and operating cycles of the assets’ battery systems.
For assets depreciated using the units-of-production method, depreciation is based on actual asset utilization relative to the estimated
total production cycles of the battery systems. Based on an expected utilization of approximately 365 operating cycles per year over
an estimated useful life of
Upon disposal of assets, the cost of the assets and the related accumulated depreciation are removed from the accounts, and gains or losses are reflected in the accompanying condensed statements of operations for the respective period.
LiGHT Proton Therapy System Equipment
On
July 1, 2026, the Company, through a reverse acquisition (see Note 3), acquired an
The LiGHT machine requires recommissioning and updates and is not yet ready for its intended use. Accordingly, it is treated as an asset under construction, and depreciation will not begin until the asset is placed into service.
Long-Lived Assets
The Company evaluates long-lived assets, other than goodwill and indefinite-lived intangible assets, for impairment whenever events or changes in circumstances (“triggering events”) indicate that their net book value may not be recoverable. The measurement of possible impairment is based upon the ability to recover the carrying value of the asset through the expected future undiscounted cash flows from the use of the asset and its eventual disposition. An impairment loss, equal to the difference between the asset’s fair value and its carrying value, is recognized when the estimated future undiscounted cash flows are less than its carrying amount. No impairment indicators were identified as of September 30, 2026 and December 31, 2025.
Goodwill
Goodwill represents the excess purchase price and related costs over the value assigned to the net tangible and identifiable intangible assets of the business acquired. Goodwill that arose from acquisition of Lixte was $94,340. Under ASC 350 Intangibles-Goodwill and Other, goodwill and other intangible assets with indefinite lives are not amortized, but instead are tested for impairment annually, or whenever events or circumstances indicate a potential impairment. The Company’s impairment testing is performed annually at December 31. Impairment of goodwill and indefinite lived intangible assets is determined by comparing the fair value of the Company’s reporting unit to the carrying value of the underlying net assets in the reporting unit. If the fair value of the reporting unit is determined to be less than the carrying value of its net assets, goodwill is deemed impaired and an impairment loss is recognized to the extent that the carrying value of goodwill exceeds the difference between the fair value of the reporting unit and the fair value of its other assets and liabilities. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker (the Company’s Chief Executive Officer) determined that there are two reporting units.
During the three months ended September 30, 2026,
the Company’s stock price declined. Based on the September 30, 2026 closing price, the market value of the Company’s outstanding
common stock was below the carrying amount of its stockholders’ equity of $
A further decline in the Company’s stock price, a failure to obtain the approvals required for conversion of the Series D Convertible Preferred Stock, or a failure to achieve projected results could indicate that the fair value of a reporting unit is below its carrying amount. In that event, the Company may be required to recognize a goodwill impairment charge, which could be material, in a future period, including in connection with its annual impairment test as of December 31, 2026.
Leases
The Company leases certain corporate office space under lease agreements. The Company determines whether a contract contains a lease at contract inception. A contract is a lease if it conveys the right to control the use of the identified asset for a period in exchange for consideration. Control is determined based on the right to obtain all of the economic benefits from use of the identified asset and the right to direct the use of the identified asset. Operating lease right-of-use assets (“ROU”) represent the right to use an underlying asset for the lease term, and operating lease liabilities represent the obligation to make lease payments. Lease liabilities are recognized at the present value of the future minimum lease payments over the lease term at the commencement date. Operating lease expense is recognized on a straight-line basis over the lease term and is included in the sales, general and administrative expense in the Company’s condensed statements of operations.
| 12 |
Revenue Recognition
The Company recognizes Sales of Product revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers. Lease revenue is recognized in accordance with FASB ASC 842, Leases.
The Company generates revenue from the sale of its mobile energy storage systems and related products, including mobile battery energy storage systems (“MBESS”), mobile transformer docking stations (“mobile docks”), and trailers for mounting and transportation of the MBESS. Revenue is recognized when control of the related products is transferred to the customer, in an amount that reflects the transaction price consideration that is expected to be received. Revenue associated with any unsatisfied performance obligation is deferred until the performance obligation is satisfied, i.e., when control of the related products is transferred to the customer. In some cases, the Company generates revenue from the short-term lease of its mobile energy storage systems. In these instances, revenue from the lease is recognized on a straight-line basis over the term of the lease.
To determine the proper revenue recognition method for contracts, the Company evaluates whether two or more contracts should be combined and accounted for as one contract and whether a single contract should be accounted for as more than one performance obligation. ASC 606 defines a performance obligation as a contractual promise to transfer a distinct good or service to a customer. A contract’s transaction price is allocated to each distinct performance obligation based on the relative standalone selling prices of the goods and services promised in the contract and recognized when, or as, the performance obligation is satisfied. The Company’s evaluation requires significant judgment, and the decision to combine a group of contracts or separate a contract into multiple performance obligations could change the amount of revenue and profit recorded in a given period.
The Company’s supply agreements and purchase orders may include multiple product deliverables, including MBESS, mobile docks, and trailers. The Company evaluates each promised good or service to determine whether it represents a distinct performance obligation under ASC 606. If a promised good or service is distinct, it is accounted for as a separate performance obligation. If the promised goods or services are not separately identifiable from other promises in the contract and are not distinct within the context of the contract, they are combined and accounted for as a single performance obligation.
The Company also evaluates whether it is the principal or agent in arrangements involving products manufactured by third parties. The Company is generally the principal when it controls the specified products before they are transferred to the customer. In making this determination, the Company considers indicators of control, including whether it is primarily responsible for fulfilling the promise to provide the specified products, whether it has inventory risk before the products are transferred to the customer, and whether it has discretion in establishing the price for the products. Based on these considerations, the Company generally concludes that it controls the products before transfer to the customer and is the principal in these arrangements. Accordingly, revenue is recognized on a gross basis for the amount of consideration to which the Company expects to be entitled.
As the Company’s contracts may include multiple product deliverables, the timing of revenue recognition depends on when control of each related performance obligation transfers to the customer. Control is transferred when the customer has the ability to direct the use of, and obtain substantially all of the remaining benefits from, the related products. The Company considers the contractual terms, including applicable shipping Incoterms (defined as logistical shipping terms that define obligations for both the buyer and seller), customer acceptance provisions, transfer of ownership, and other relevant contract terms, in determining when control transfers.
For certain Ex-Works (“EXW”) arrangements (defined as the lowest level of responsibility for the seller), the customer may take ownership and control of products prior to physical shipment from the Company’s facility. In these situations, the Company evaluates whether the customer has obtained control of the products in accordance with ASC 606. When products have been specifically identified to the customer, are no longer available for use by the Company, and the customer has accepted ownership and assumed the associated risks related to the products, control may transfer prior to physical shipment. For EXW transactions where the customer obtains control at the Company’s facility, revenue is recognized when the customer assumes ownership and control of the goods. For other EXW transactions where control has not transferred, revenue is recognized when the applicable transfer criteria have been met.
For Delivered Duties Paid (“DDP”) arrangements, revenue is recognized when the goods are delivered to the customer’s specified destination and the Company has satisfied its remaining delivery obligations.
| 13 |
The Company’s contracts give rise to several types of variable consideration, including contract modifications (change orders) and other terms that can either increase or decrease the transaction price. The Company estimates variable consideration as the most likely amount to which it expects to be entitled. The Company includes estimated amounts in the transaction price to the extent it believes it has an enforceable right and it is probable that a significant reversal of cumulative revenue recognized will not occur. The estimates of variable consideration and the determination as to whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current, and forecasted) that is reasonably available at the time. Change orders and incentives are evaluated to determine whether they represent separate performance obligations or modifications to existing performance obligations. When change orders are not distinct from the existing contract due to the significant integration services provided in the context of the contract, they are accounted for as a modification to the existing contract and performance obligation. The effect of contract modification on the transaction price, and the Company’s measure of progress for the performance obligation to which it relates, is recognized as an adjustment to revenue on a cumulative catch-up basis, when applicable. In some cases, settlement of contract modifications may not occur until after completion of work under the contract.
The Company generally provides limited assurance-type warranties for work performed under its contracts. Product and installation warranties are provided by the equipment manufacturers and the Company within the context of each customer contract. In certain cases, the Company may be liable for re-installation costs resulting from faulty hardware. The warranty periods typically extend for a limited duration after control of the mobile energy storage system is transferred to the customer. Historically, assurance-type warranty claims have not resulted in material costs being incurred.
Certain contracts include extended service-type warranties. The Company offers extended warranties to customers for a period of up to ten years. Such warranties are considered to be separate performance obligations to which the related consideration is appropriately allocated based on the relative standalone selling price and recognized over the term of the warranty. There was no revenue related to extended warranties during the nine months ended September 30, 2026 and 2025.
Certain contracts include performance-type warranties. The Company offers performance warranties to customers for a period of up to ten years. Such warranties are evaluated to determine whether they represent separate performance obligations under ASC 606. When such warranties are considered to be separate performance obligations, the related consideration is appropriately allocated based on the relative standalone selling price and recognized over the term of the warranty. Revenue related to performance-type warranties was de minimis during the nine months ended September 30, 2026 and 2025.
The timing of revenue recognition, billings, and cash collections results in billed accounts receivable, unbilled revenue, deferred revenue, and customer deposits. Amounts are billed in accordance with agreed-upon contractual terms. Generally, billings and customer deposits occur prior to revenue recognition, resulting in contract liabilities presented in the balance sheet as deferred revenue and customer deposits. Deferred revenue represents the unearned revenue on cash receipts for consideration the Company has received on contracts for which the related performance obligation has not been satisfied. The Company expects deferred revenue at September 30, 2026 to be recognized as the related performance obligations are satisfied in accordance with the terms of the underlying contracts.
Revenue consisted of the following for the nine months ended September 30, 2026 and 2025:
Schedule Of Revenues
| 2026 | 2025 | |||||||
Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Sales of product | $ | $ | ||||||
| Lease revenue | ||||||||
| Other revenue | ||||||||
| Total | $ | $ | ||||||
| 14 |
Cost of Revenues
Cost of revenue consists primarily of costs of sold units and ancillary equipment, delivery and freight costs, expenses related to employee trips to customer sites for training, on-site acceptance testing (“OSAT”), and service work on deployed units.
Advertising Costs
Advertising
costs are expensed as incurred and are included in sales, general, and administrative expenses on the condensed statement of operations.
Total advertising expense was approximately $
Research and Development Costs
Research
and development costs are expensed as incurred and are included in research and development expenses on the condensed statements of operations.
Costs mostly consist of engineering, testing fees, and related product costs. In addition, research and development costs consist primarily
of fees paid to consultants and contractors, and other expenses relating to the negotiation, design, development, conduct and management
of clinical trials with respect to the Company’s clinical compound and product candidate. Research and development costs also include
the costs to manufacture compounds used in research and clinical trials, which are charged to operations as incurred. The Company’s
inventory of LB-100 for clinical use has been manufactured separately in the United States and in the European Union in accordance with
the laws and regulations of such jurisdictions. Total research and development expense was approximately $
Loss per Common Share
Basic earnings (loss) per share is computed by dividing the net income (loss) applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed by dividing the net income applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. The computation excludes potential common shares when their effect is antidilutive.
For the nine months ended September 30, 2026 and 2025, the calculations of basic and diluted loss per share are the same because potential dilutive securities would have had an anti-dilutive effect. The potentially dilutive securities consisted of the following:
Schedule of Anti dilutive Securities
| 2026 | 2025 | |||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| Warrants (excluding pre-funded warrants) | ||||||||
| Stock options | ||||||||
| Common shares issuable | - | |||||||
| Restricted stock units | ||||||||
| Total | ||||||||
Stock-Based Compensation
The Company accounts for stock-based compensation in accordance with ASC 718, Compensation—Stock Compensation, which establishes the accounting treatment for transactions in which an entity exchanges its equity instruments for goods or services. Under the provisions of ASC 718, the measurement of the value of employee services received in exchange for an award of an equity instrument is based on the grant-date fair value of the award. Prior to issuance of the awards, the Company is not under any obligation to issue stock options or restricted stock units (“RSUs”). The award vests over a specified period determined by the Company’s Board of Directors. The measurement date of the grant is also the date of the award. The fair value of options is expensed ratably during the specified vesting period.
| 15 |
The Company accounts for stock-based payments to non-employees in accordance with FASB ASU 2018-07—Compensation—Stock Compensation (topic 718): improvements to nonemployee share-based payment accounting. Non-employee stock-based compensation is granted at the Board of Director’s discretion to select individuals.
The Company estimates the fair value of stock awards on the date of grant using a Black-Scholes valuation model, which requires management to make certain assumptions that are complex, subjective, and generally require significant judgment to determine regarding: (i) the expected volatility in the market price of the Company’s common stock; (ii) dividend yield; (iii) risk-free interest rates; and (iv) the period of time employees are expected to hold the award prior to exercised (referred to as the expected holding period).
The estimated volatility is based on the historical volatility of the Company’s common stock, calculated utilizing a look-back period approximately equal to the contractual life of the stock option being granted. The Company has not declared or paid dividends in the past and does not currently expect to do so in the foreseeable future. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant for bonds with maturities ranging from one month to five years.
The expected term represents the period that the stock options are expected to be outstanding. The expected term of options granted to employees and non-employee directors is determined using the “simplified” method, as illustrated in ASC 718, as the Company does not have sufficient exercise history to determine a better estimate of expected term. Under this approach, the expected term is based on the midpoint between the vesting date and the end of the contractual term of the option. Forfeitures are recognized as they occur.
Warrants
The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”), and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. The Company has determined that the warrants issued in the February 2025 equity financing, and the July 2025 equity financings meet the requirements for equity classification. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all of the criteria for equity classification, the warrants are required to be liability-classified and recorded at their initial fair value on the date of issuance and remeasured at fair value at each reporting date. At September 30, 2026 and December 31, 2025, the Company did not have any liability-classified warrants.
Stock Granted to Employees and Non-Employees in Lieu of Cash Payments
The Company periodically issues share-based awards to employees, non-employees, and consultants for services rendered. Stock options vest and expire according to the terms established at the grant’s issuance date. Stock grants are measured at the grant date fair value. Stock-based compensation cost is measured at fair value on the grant date and is generally recognized as an expense in the statement of operations ratably over the requisite service period or vesting period. Recognition of compensation expense for non-employees occurs in the same period and in the same manner as if the Company had paid cash for the services.
Related Parties
In accordance with ASC 850, Related Party Disclosures, a party is considered to be related to the Company if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management, and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.
| 16 |
Derivative Financial Instruments
The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.
The Company uses Level 3 inputs for its valuation methodology for the derivative liabilities as their fair values were determined by using a Binomial pricing model. The Company’s derivative liabilities are adjusted to reflect fair value at each reporting date, with any increase or decrease in the fair value being recorded in the statement of operations.
To determine the number of authorized but unissued shares available to satisfy outstanding convertible securities, the Company uses a sequencing method to prioritize its convertible securities as prescribed by ASC 815-40-35, Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40-35). At each reporting date, the Company reviews its convertible securities to determine whether their classification is appropriate.
Foreign Currency
The consolidated financial statements are presented in the United States dollar, which is the functional and reporting currency of the Company and its subsidiaries, including the Company’s United Kingdom subsidiary.
For transactions denominated in a foreign currency, the Company purchases the required foreign currency on an as-needed basis to pay the related cost or expense, which is converted into United States dollars at the exchange rate in effect on the transaction date. Realized gains or losses on these purchases are recorded as foreign currency gain (loss) in the consolidated statement of operations.
Because the United Kingdom subsidiary uses the United States dollar as its functional currency, its foreign-currency-denominated monetary items — principally its pound sterling operating lease liability — are remeasured into United States dollars at period-end exchange rates, with the resulting remeasurement gains and losses recorded in the consolidated statement of operations. Nonmonetary items, including the operating lease right-of-use asset and the LiGHT proton therapy system equipment, are carried at historical exchange rates and are not subsequently remeasured.
The Company periodically incurs a cost or expense in a foreign jurisdiction denominated in a local currency. The Company purchases the required foreign currency to pay such cost or expense on an as-needed basis. Such cost or expense is converted into United States dollars for financial statement purposes based on the foreign currency conversion rate in effect on the transaction date. The Company purchases the requisite foreign currency to pay such cost or expense on an as-needed basis. Any gain or loss resulting from the purchase of the foreign currency is included as realized foreign currency gain (loss) in the consolidated statement of operations.
During
the three months ended September 30, 2026, the Company incurred various costs and expenses denominated in Euros, which were converted
into United States dollars at the average rate of
As of September 30, 2026 and December 31, 2025, the Company did not hold any currencies other than the United States dollar in its bank accounts and was not a party to any foreign currency forward or exchange contracts.
| 17 |
Fair Value of Financial Instruments
Fair value of financial and non-financial assets and liabilities is defined as an exit price, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three-tier hierarchy for inputs used to measure fair value, which prioritizes the inputs to valuation techniques used to measure fair value, is as follows:
Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.
Level 3 – unobservable inputs based on the Company’s assumptions used to measure assets and liabilities at fair value.
A financial asset or liability classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the assets and liabilities being measured and their placement within the fair value hierarchy.
The carrying value of financial instruments, which consists of accounts payable and accrued expenses, is considered to be representative of their respective fair values due to the short-term nature of those instruments.
Concentration of Risk
Supply Risk – The Company is dependent on its suppliers, some of which are single source suppliers, and the inability of these suppliers to deliver necessary components of the Company’s products in a timely manner at prices, quality levels, and volumes acceptable to the Company, or the Company’s inability to efficiently manage these components from these suppliers, could have a material adverse effect on the Company’s business, prospects, financial conditions, and operating results.
Although all of the Company’s contract manufacturers’ current manufacturing facilities are operational, and the Company continues to increase output and add additional capacity and is working with each supplier on meeting, ramping, and sustaining production, the ability to sustain this trajectory depends, among other things, on the readiness and solvency of suppliers amid macroeconomic factors.
Credit Risk – At various times during the year, the amount of cash on deposit may exceed the insured limit by the U.S. Federal Deposit Insurance Corporation, which potentially subjects the Company to credit risk. The Company maintains its cash at high-quality institutions.
Sales.
During the three months ended September 30, 2026, three customers accounted for
Deferred
Revenue – Five customers accounted for
Segment Information
The
Company’s Chief Executive Officer (“CEO”) is our chief operating decision maker (“CODM”) and evaluates
performance and makes operating decisions regarding resource allocation based on financial data presented as a whole, as there are no
separate operating entities. Because our CODM evaluates financial performance on the Company as a whole, the Company evaluates its operations
through
| 18 |
Recent Accounting Pronouncements
In November 2024, the FASB issued ASU No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses which includes amendments that require disclosure in the notes to financial statements of specified information about certain costs and expenses, including purchases of inventory; employee compensation; and depreciation, amortization and depletion expenses for each caption on the income statement where such expenses are included. The amendments are effective for the Company’s annual periods beginning January 1, 2027, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is evaluating this ASU to determine its impact on the Company’s disclosures.
Other recent accounting pronouncements issued by the FASB, its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.
Note 3. Reverse Acquisition
The
July 1, 2026 merger made NOMAD a wholly owned subsidiary of the Company. The share consideration delivered to former NOMAD holders comprised
Identification of the Accounting Acquirer
Although
Lixte is the legal acquirer, NOMAD was identified as the accounting acquirer in accordance with ASC 805-10-55-11 through 55-15, based
on an evaluation of all pertinent facts and circumstances. In the merger, former NOMAD stockholders received
The Company also considered that two members of its board of directors following the merger were designated by NOMAD. In addition, NOMAD is an operating company with revenue-generating products, customers and employees, whereas Lixte was a clinical-stage company with no revenue, and the implied fair value of NOMAD based on the merger consideration significantly exceeded the fair value of Lixte. Following the merger, the Company was renamed Nomad Power Solutions, Inc., and NOMAD’s business became the Company’s primary business. Based on the weight of these factors, the Company concluded that NOMAD is the accounting acquirer.
The acquired operations constitute a business. The deemed consideration is the fair value of interests that NOMAD would have issued to give the former legal-parent owners their resulting ownership interest. As of September 30, 2026, management has not yet finalized the purchase price allocation. In accordance with ASC 805, the Company made a provisional allocation of the purchase price based on the estimated fair values of the assets acquired and liabilities assumed. The fair values of the assets acquired, as set forth below, are considered provisional and subject to adjustment as additional information is obtained through the purchase price measurement period (a period of up to one year from the closing date). Any prospective adjustments through the purchase price measurement period would change the fair value allocation as of the acquisition date.
Schedule of Business Acquisition
| Fair Value | ||||
| Fair value of consideration: | ||||
| Cash | $ | |||
| Series D preferred shares ( | ||||
| Common stock ( | ||||
| Fair value of noncontrolling interests acquired | ||||
| Total purchase price | $ | |||
| Provisional allocation of the consideration to the fair value of assets acquired and liabilities assumed: | ||||
| Cash | $ | |||
| Prepaid and other current assets | ||||
| Note receivable | ||||
| LiGHT proton therapy system equipment | ||||
| Operating lease right-of-use assets | ||||
| Accounts payable | ( | ) | ||
| Research and development contract liabilities | ( | ) | ||
| Operating lease liabilities assumed | ( | ) | ||
| Net identifiable assets acquired | ||||
| Goodwill | $ | |||
| 19 |
Acquisition-related
expenses of $
The supplemental unaudited pro forma information below gives effect to the acquisition as if it occurred on January 1, 2025. It is illustrative and does not predict actual or future performance.
Schedule of Supplemental Unaudited Pro Forma Information
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Sales | $ | $ | $ | $ | ||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
4. Employee Tax Withholding Receivable
In
connection with the vesting and settlement of restricted stock units (“RSUs”), the Company is required to collect
applicable employee payroll taxes and remit both employee and employer payroll taxes in accordance with applicable tax deposit
requirements. As of September 30, 2026, the Company had recorded an aggregate payroll tax liability of $
5. Inventory
Inventory by category consisted of the following:
Schedule of Inventory
September 30, 2026 | December 31, 2025 | |||||||
| Finished goods | $ | $ | ||||||
| Work in progress | ||||||||
| Spare parts inventory | ||||||||
| Total inventory | $ | $ | ||||||
6. Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consisted of the following:
Schedule of Prepaid Expenses and Other Current Assets
September 30, 2026 | December 31, 2025 | |||||||
| Prepaid royalty expense | $ | $ | ||||||
| Prepaid insurance | ||||||||
| Prepaid legal expenses | ||||||||
| Prepaid commissions | - | |||||||
| Other prepaid and other current assets | ||||||||
| Total prepaid expenses and other current assets | $ | $ | ||||||
| Total prepaid expenses and other current assets | $ | $ | ||||||
| 20 |
7. LiGHT Proton Therapy System Equipment
LiGHT Proton Therapy System Equipment (“LiGHT”), net, consisted of the following:
Schedule of Light Proton Therapy System Equipment
September 30, 2026 | December 31, 2025 | |||||||
| LiGHT Proton Therapy System Equipment | $ | $ | - | |||||
| Accumulated depreciation | - | - | ||||||
| Total | $ | $ | - | |||||
On
July 1, 2026, we acquired the LiGHT machine through a reverse acquisition (see Note 3). The LiGHT machine is located at a leased facility
at the Daresbury Laboratory in the United Kingdom and is not currently operational. The machine has not been placed in service; accordingly,
no depreciation has been recognized.
During
the period ended September 30, 2026, $
8. Revenue Generating Equipment
Revenue-generating equipment, net, consisted of the following:
Schedule of Revenue Generating Equipment
September 30, 2026 | December 31, 2025 | |||||||
| Revenue-generating equipment | $ | $ | ||||||
| Accumulated depreciation | ( | ) | ( | ) | ||||
| Total revenue-generating equipment, net | $ | $ | ||||||
| Revenue generating equipment net | $ | $ | ||||||
Revenue-generating
depreciation expense was $
9. Property and Equipment
Property and equipment, net, consisted of the following:
Schedule of Property and Equipment
September 30, 2026 | December 31, 2025 | |||||||
| Property and equipment | $ | $ | ||||||
| Computer equipment | ||||||||
| Construction in progress | - | |||||||
| Accumulated depreciation | ( | ) | ( | ) | ||||
| Total | $ | $ | ||||||
Depreciation
expense was $
10. Accrued Expenses
Accrued liabilities consisted of the following:
Schedule of Accrued Liabilities
September 30, 2026 | December 31, 2025 | |||||||
| Trade vendor accrual | $ | - | $ | |||||
| Accrued payroll | ||||||||
| Accrued taxes (excluding payroll taxes) | ||||||||
| Accrued other | ||||||||
| Total | $ | $ | ||||||
| 21 |
11. Debt
Debt consists of the following at September 30, 2026 and December 31, 2025:
Schedule of Short Term Debt
September 30, 2026 | December 31, 2025 | |||||||
| Streeterville Capital, LLC | $ | $ | - | |||||
| Bay Point Capital Partners II, LP | - | |||||||
| HalfBrothers Capital Limited | - | |||||||
| Northern Horizon Investments, Inc. | - | |||||||
| Mezzanine Loans – ($ | ||||||||
| Other financing | - | |||||||
| Accrued interest | ||||||||
| Debt discount | ( | ) | ( | ) | ||||
| Total | ||||||||
| Less current portion | ||||||||
| Non-current portion | $ | - | $ | |||||
Streeterville Capital, LLC
On
September 28, 2026, Nomad Power Solutions, Inc. (the “Company”) entered into a note purchase agreement with Streeterville
Capital, LLC (“Streeterville”) and issued a secured promissory note with an original principal amount of $
The
Note bears interest at
Beginning
six months after funding, Streeterville may require cash redemptions of up to $
The Note is secured by a first-position security interest in the Company’s existing and subsequently acquired assets, including its equity interests in subsidiaries, subject to permitted liens. The Note is guaranteed by Lixte Biotechnology, Inc., Nomad Transportable Power Systems, Inc. and Liora Technologies Europe Ltd.
| 22 |
The
original issue discount and financing costs, totaling $
The carrying amount of Debt was as follows:
Schedule of Debt Outstanding
| September 30, 2026 | ||||
| Principal and interest outstanding | $ | |||
| Less: unamortized original issue discount | ( | ) | ||
| Less: unamortized financing costs | ( | ) | ||
| Note payable, net — current | $ | |||
Accrued
interest of $
Bay Point Capital Partners II, LP
On
February 12, 2024, NOMAD entered into a financing arrangement with Bay Point Capital Partners II, LP (“Bay Point Loan”)
for $
The
Bay Point Loan bears interest annually at
In
June 2026, $
Lixte Biotechnology Holdings, Inc.
On June 16, 2026, in connection with its merger with Lixte (see Note 3),
NOMAD received an advance of
$
Half Brothers Capital Limited
On
February 12, 2024, NOMAD entered into a loan and security agreement with Half Brothers Capital Limited (the “HBCL Loan”).
The HBCL Loan bears interest annually at
| 23 |
Northern Horizon Investments Inc.
On
February 12, 2024, NOMAD entered into a loan and security agreement with Northern Horizon Investments, Inc. (the “NHI Loan”).
The NHI Loan bears interest annually at
Mezzanine Loans – Related Parties
During
the nine months ended September 2026, the Company received approximately $
These loans had no stated maturity date and did not bear interest.
The
Company also incurred approximately $
Mezzanine Loans – Related Parties – In Default
During
2025, NOMAD received approximately $
The
Mezzanine loans generally bear interest at rates of
During
2025, NOMAD repaid approximately $
During
the six months ended June 30, 2026, NOMAD repaid approximately $
The
loans were in default as of December 31, 2025 and were accruing interest at the applicable default rate of
Mezzanine Loans – Non-Related Parties – In Default
During
2025, NOMAD received approximately $
The
Mezzanine loans generally bear interest at rates of 20% per annum and have short-term maturities. The loan agreements generally provide
for a minimum interest period and equity-based loan fees. Upon an event of default, including failure to repay amounts due within the
applicable period following maturity, the lender may, if permitted by applicable law, increase the interest rate to
| 24 |
During
2025, NOMAD repaid approximately $
In July 2026, the Company repaid the mezzanine loan agreements to non-related parties in full.
Other Financing
On
December 24, 2025, NOMAD entered into an agreement pursuant to which NOMAD received $
On
February 6, 2026, NOMAD entered into an agreement pursuant to which NOMAD received $
Under the agreements, NOMAD is required to remit a specified percentage of deposits into its designated bank account to satisfy the amount purchased. The difference between the net proceeds received and the total contractual repayment amount, including applicable fees, is accounted for as a discount and financing costs and is recognized as interest expense over the term of the financing using the effective interest method.
As
of December 31, 2025, the Company had approximately $
During
the nine months ended September 30, 2026, the Company repaid approximately $
Future minimum payments are due as follows during the years ended December 31:
Schedule of Future Minimum Payments
| Description | Amounts | |||
| 2026 (remaining) | $ | |||
| 2027 | ||||
| 2028 and thereafter | - | |||
| Total | $ | |||
12. Leases
The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. Leases with an initial term of 12 months or less are not included on the balance sheets.
During
2023, NOMAD entered into two new operating lease agreements for office space in Idaho and Vermont. The Idaho lease requires monthly
payments of approximately $
| 25 |
On
July 1, 2026, the Company assumed as part of its reverse acquisition (see Note 3), a two-year lease agreement with United Kingdom Research
and Innovation for the rental of the premises at UKRI Daresbury that houses the acquired LiGHT system equipment. The lease has a quarterly
base rent of GBP
Operating
lease expense was approximately $
The
Company’s operating lease right of use asset was $
The
Company’s operating lease liability balance was $
Maturities of the Company’s operating lease liabilities are as follows as of September 30, 2026:
Schedule of Maturities of Operating Lease Liabilities
As of September 30, 2026 | ||||
| 2026 (remaining) | $ | |||
| 2027 | ||||
| 2028 | ||||
| Thereafter | - | |||
| Total | ||||
| Less: Imputed interest | ( | ) | ||
| Total operating lease liability | $ | |||
Supplemental cash flow information related to operating leases is as follows:
Schedule of Supplemental Cash Flow Information Related to Operating Leases
Nine months ended September 30, 2026 | ||||
| Cash payments for operating leases | - | |||
| Weighted-average remaining lease term (in years) | ||||
| Weighted-average discount rate | % | |||
13. Derivative Liability
On
June 7, 2026, pursuant to the Stock Purchase Agreement with pursuant to a Securities Purchase Agreement dated June 7, 2026 (see Note
15), NOMAD granted Aldersgate Capital Ltd. and BenEth Capital LLC an aggregate right to convert
| 26 |
The following tables summarize the derivative liability:
Schedule Of Derivative Liabilities At Fair Value
September 30, 2026 | June 7, 2026 | |||||||
| Stock price | $ | - | $ | |||||
| Exercise price | $ | - | $ | |||||
| Risk free interest rate | - | % | ||||||
| Expected volatility | - | % | ||||||
| Expected life in years | - | |||||||
| Expected dividend rate | - | % | ||||||
| Number of warrants | - | |||||||
| Fair value of derivative liability | $ | - | $ | |||||
The following table provides a roll-forward of the derivative liability measured at fair value on a recurring basis using unobservable level 3 inputs for the period ended September 30, 2026, as follows:
Schedule of Derivative Liability Measured At Fair Value
| Fair Value of Derivative Warrant Liability | ||||
| Balance, December 31, 2025 | $ | - | ||
| Initial recording of fair value of warrant derivative liability | ||||
| Change in fair value of warrant derivative liability | ||||
| Reclassifications to equity | ( | ) | ||
| Balance, September 30, 2026 | $ | - | ||
14. Commitments and Contingencies
Legal Proceedings
The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The Company is not party to any material legal proceedings as of September 30, 2026.
On December 2, 2025, Green Mountain Electric Supply, Inc. (“GMES”) filed a Civil Complaint against NOMAD for nonpayment of outstanding invoices related to industrial products ordered and received by NOMAD. The Company does not dispute the amounts owed to GMES and has communicated the intention to settle the debt owed to GMES and have the action filed against the Company dismissed. On August 13, 2026, GMES filed a Satisfaction of Judgment for dismissal of the action filed.
| 27 |
Royalty Agreement
On
April 1, 2022, NOMAD entered into a royalty agreement with RER. Under the royalty agreement, the Company is required to pay RER
3.5% of the gross proceeds from the sale of the first six NOMAD units as well as any new units produced from the remaining gross proceeds
during the term of the note. The Company is subject to paying the royalty upon receipt of cash from the customer. NOMAD paid approximately
$
Clinical Trial and Monitoring Agreements
As
of September 30, 2026, the Company had remaining contractual commitments of approximately $
The Company’s principal ongoing clinical trials include the following:
| ● | Netherlands Cancer Institute. A Phase 1b clinical trial evaluating LB-100 in combination with atezolizumab in patients with microsatellite-stable metastatic colorectal cancer began in August 2024. Three patients have been enrolled. The Company has no obligation to fund the clinical trial costs but provides LB-100 and separately funds certain monitoring activities. | |
| ● | Spanish
Sarcoma Group (“GEIS”). The Phase 1b portion of a clinical trial evaluating LB-100 in combination with doxorubicin
in advanced soft tissue sarcoma has been completed. In March 2025, the agreement was amended to eliminate the Company’s approximately
$ | |
| ● | MD Anderson Cancer Center. An investigator-initiated Phase 1b/2 clinical trial is evaluating LB-100 in combination with dostarlimab in patients with ovarian clear cell carcinoma. Thirty patients have been enrolled, and the trial is expected to be completed by December 31, 2027. The Company provides LB-100 but has no contractual obligation to fund the clinical trial costs. |
The
Company has monitoring agreements with Theradex covering the MD Anderson, GEIS and Netherlands Cancer Institute trials. As of September
30, 2026, the remaining commitments under these agreements were approximately $
Patent License Agreement
In February 2024, Lixte entered into an exclusive patent license agreement with institutes of the National Institutes of Health (“NIH”) covering certain jointly developed intellectual property related to the use of LB-100 in cancer treatment. The license generally continues on a country-by-country basis until expiration of the last valid licensed patent claim, unless earlier terminated.
The
Company is required to pay the NIH an annual minimum royalty of $
Expense
under the license agreement was $
| 28 |
Other Agreements
Under
a development collaboration agreement with the Netherlands Cancer Institute and Oncode Institute, the Company is funding certain preclinical
research involving LB-100. As of September 30, 2026, the remaining commitment under the agreement was approximately $
The
Company incurred expenses under its agreement with BioPharmaWorks of $
The
Company also contracts with MRI Global for stability testing, storage and distribution of LB-100. Related expense was $
Serious Adverse Events
The principal investigator of the Netherlands Cancer Institute colorectal cancer trial is investigating two serious adverse events observed in the first two enrolled patients. One patient experienced dyspnea associated with lung toxicity considered possibly or probably related to the combination of LB-100 and atezolizumab and subsequently died in the context of metastatic colorectal cancer and dyspnea. The second patient experienced fever and aphasia considered possibly or probably related to the combination and fully recovered following supportive treatment.
The Institutional Review Board placed the trial on enrollment hold and requested additional information regarding the events and the potential effects of the drug combination. The investigator submitted a response that included updated safety information for LB-100. The response was satisfactory and since January 2026 the trial is actively recruiting patients.
15. Stockholders’ Equity
Preferred Stock
The
Company is authorized to issue a total of
On
July 1, 2025, the Company filed amendment to Certificate of Incorporation by filing Certificate of Designations, Preferences, Rights
and Limitations of its Series B Convertible Preferred Stock with the Delaware Secretary of State. The Company has designated a total
of
On
July 1, 2026, the Company completed its reverse merger with Nomad Transportable Power Systems, Inc. (“NOMAD”) (see Note 3).
As partial merger consideration, the Company issued
If stockholder approval is not obtained, the NASDAQ Exchange Cap will remain in effect, and the holders of Exchange Preferred Shares will not be able to convert their shares of Preferred Stock into shares of Common Stock in excess of the NASDAQ Exchange Cap. This limitation would result in the Company being required to pay a cumulative dividend at a rate of 7% per annum of the Liquidation Value, as defined in the Certificate of Designations (the “Accruing Dividend”). The Accruing Dividend will be cumulative, will compound annually on each anniversary of the Dividend Commencement Date, and will be payable quarterly in arrears in cash on the last Business Day of each calendar quarter, commencing with the first full calendar quarter ending after the Dividend Commencement Date. Any Accruing Dividend that has accrued but remains unpaid shall be paid in full upon the earlier of (i) conversion of the applicable shares of Series D Non-Voting Preferred Stock, (ii) redemption or repurchase of such shares, or (iii) a Liquidation.
Common Stock
The
Company is authorized to issue a total of
| 29 |
2026 Activity
During the nine months ended September 30, 2026, the Company issued the following Series D Convertible Preferred Stock and common shares:
| ● | ||
| ● | ||
| ● | ||
| ● | ||
| ● | ||
| ● | ||
| ● | ||
| ● | ||
| ● | ||
| ● |
In addition, during the nine months ended September 30, 2026:
| ● | The
Company issued pre-funded warrants issuable at the time of the reverse acquisition (see Note
3) for an aggregate amount of fifty percent (50%) of the fully diluted capitalization of
the Company in exchange for $ |
2025 Activity
During the nine months ended September 30, 2025, the Company issued the following common shares:
| ● | ||
| ● | ||
| ● |
16. Share Based Compensation
The Company periodically issues common stock, stock options and Restricted Stock Units (RSU) as incentive compensation to directors and as compensation for the services of employees, contractors, and consultants of the Company.
| 30 |
Restricted Stock Units
A summary of the Company’s restricted stock unit (“RSU”) activity for the nine months ended September 30, 2026 is presented below:
Schedule of Restricted Stock Units
| Unvested Shares | Issuable Shares | Fair Value at Date of Issuance | Weighted Average Grant Date Fair Value | |||||||||||||
| Balance, December 31, 2025 | - | $ | ||||||||||||||
| Assumed on reverse acquisition | - | - | ||||||||||||||
| Granted | - | |||||||||||||||
| Vested | ( | ) | ( | ) | - | |||||||||||
| Issued | - | ( | ) | - | - | |||||||||||
| Balance, September 30, 2026 | - | $ | $ | |||||||||||||
In
April 2026, NOMAD granted
The granting of RSUs under the Plan entitles recipients to receive shares of the Company’s common stock upon satisfaction of the applicable vesting conditions. Vesting conditions may include immediate vesting, a three-year time-based vesting schedule, an eighteen-month time-based vesting schedule, or vesting upon liquidation.
The liquidity event condition will be satisfied upon the first to occur of 1) the declaration that an Initial Public Offering (“IPO”) is effective and 2) the time immediately prior to the consummation of a Change in Control. As of December 31, 2025, management has determined that it cannot determine when, or if, a liquidity event will occur.
In
April 2026, the Company granted
On
July 1, 2026, the Board of Directors of the Company approved the grant of
During
the nine months ended September 30, 2026 and 2025, the Company recognized stock-based compensation expense of $
| 31 |
Stock Options
A summary of stock option activity, including options to acquire 28,750 shares of common stock that were issued in the form of stock warrants, during the nine months ended September 30, 2026, is as follows:
Schedule of Stock Option Activity
| Number of Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life (in Years) | ||||||||||
| Stock options outstanding at December 31, 2025 | $ | |||||||||||
| Assumed in reverse acquisition | ||||||||||||
| Granted | ||||||||||||
| Exercised | ( | ) | ||||||||||
| Cancelled | ( | ) | ||||||||||
| Expired | ( | ) | ||||||||||
| Stock options outstanding at September 30, 2026 | $ | |||||||||||
| Stock options exercisable at September 30, 2026 | $ | |||||||||||
The Company periodically issues stock options as incentive compensation to directors and as compensation for the services of employees, contractors, and consultants of the Company.
As
of September 30, 2026, unexpired stock options for
During
the nine months ended September 30, 2026, the Company granted
During
the nine months ended September 30, 2026 and 2025, the Company recorded stock compensation expense of $
As
of September 30, 2026,
At September 30, 2026, the outstanding common stock options, including options issued in the form of warrants, are exercisable at the following prices per common share:
Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants
| Exercise Prices | Options Outstanding (Shares) | Options Exercisable (Shares) | ||||||||
| $ | ||||||||||
| $ | ||||||||||
| $ | ||||||||||
| $ | ||||||||||
| $ | ||||||||||
| $ | ||||||||||
| $ | ||||||||||
| $ | ||||||||||
| $ | ||||||||||
| $ | ||||||||||
| $ | ||||||||||
Based
on the closing fair market value of $
| 32 |
Warrants
A summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company’s public offerings, but excluding pre-funded warrants, for the nine months ended September 30, 2026, is presented below.
Schedule of Pre-Funded warrants
Number of Warrant | Weighted- Average Exercise Price | Weighted-Average Remaining Contractual Term (Years) | Aggregate Intrinsic Value | |||||||||||||
| Balance at December 31, 2025 | $ | $ | ||||||||||||||
| Assumed in reverse acquisition | - | |||||||||||||||
| Granted | - | |||||||||||||||
| Exercised | ( | ) | - | |||||||||||||
| Forfeited and expired | - | - | ||||||||||||||
| Balance at September 30, 2026 | ||||||||||||||||
On
June 7, 2026, pursuant to the Stock Purchase Agreement with pursuant to a Securities Purchase Agreement dated June 7, 2026 (see Note
13), the Company granted Aldersgate Capital Ltd. and BenEth Capital LLC an aggregate right to convert
At September 30, 2026, the outstanding warrants are exercisable at the following prices per common share:
Schedule of Warrants Outstanding and Exercisable
| Exercise Price | Warrants Outstanding (Shares) | |||||
| $ | ||||||
| $ | ||||||
| $ | ||||||
| $ | ||||||
During
the periods presented, the Company issued pre-funded warrants, each of which is exercisable immediately upon issuance at a de minimis
exercise price of $
Due to their economic characteristics, pre-funded warrants function as share-like instruments, rather than traditional warrants with a substantive exercise price or term. Therefore, including them together with standard warrants in the warrant roll-forward would significantly distort both the weighted-average exercise price and the weighted-average remaining contractual life, rendering those disclosures not meaningful. As a result, the Company presents pre-funded warrants separately from standard common stock warrants in the tables below. The pre-funded warrants are excluded from weighted-average exercise price and remaining life due to their de-minimis strike price and share-like characteristics.
| 33 |
The following table presents a summary of activities related to pre-funded warrants for the nine months ended September 30, 2026:
Summary of Activities Related to Common Stock Warrants
| Number of Shares | ||||
| Pre-funded warrants outstanding at December 31, 2025 | ||||
| Issued | ||||
| Exercised | ( | ) | ||
| Expired | - | |||
| Pre-funded warrants outstanding at September 30, 2026 | ||||
The following table presents a summary of total number of common stock warrants and pre-funded warrants outstanding as of September 30, 2026:
Schedule of Common Stock Warrants and Pre-Funded Warrant
| Warrant Type | Warrants Outstanding (Shares) | |||
| Common stock warrants | ||||
| Pre-funded warrants | ||||
| Total warrants outstanding | ||||
Approximately
In
July 2026, the Company received notices from warrant holders electing, pursuant to the fundamental transaction provision, to receive
cash payments, determined using a Black-Scholes valuation, for
The
30-trading-day election period expired on August 12, 2026. No other holders elected cash settlement within that period. Accordingly,
the Company’s aggregate obligation under this provision is limited to approximately $
17. Related Party Transactions
Transition Agreement with Related Party
On
July 11, 2024, NOMAD entered into a Transition Agreement and General Release (the “Transition Agreement”) with former
CEO, Paul Coombs, in connection with the termination of his employment with the Company effective July 11, 2024. Pursuant to the Transition
Agreement, and in consideration for a general release of claims and Mr. Coombs’ compliance with certain continuing obligations,
the Company agreed to pay Mr. Coombs an aggregate of $
On
September 10, 2026,
| 34 |
In connection with the Transition Agreement, the Company and Mr. Coombs also entered into a Consulting Services Agreement pursuant to which Mr. Coombs agreed to provide consulting, promotional and brand ambassador services to the Company. The consulting agreement commenced on July 10, 2024 and continued through July 9, 2026. Under the consulting agreement, the Company paid Mr. Coombs a nominal monthly fee for a minimum of five hours of consulting services per month whereby he served as an independent contractor and was generally responsible for his own expenses unless the Company approved them in advance.
For
the year ended December 31, 2025, the Company recognized $
Offtake Agreements
NOMAD had signed an Offtake Agreement for batteries with KORE Power, Inc. (“KORE Power”) a stockholder of NOMAD, effective January 31, 2022. Under the agreement, KORE Power was to supply batteries according to NOMAD’s production schedule. The purchase of the batteries is facilitated through KORE Solutions, Inc. (“KORE Solutions”), a stockholder of NOMAD and wholly-owned subsidiary of KORE Power, collectively (“KORE”).
NOMAD signed a Master Supply Amendment with KORE Power, effective December 1, 2023, to amend and replace the Offtake Agreement previously entered into between NOMAD and KORE Power. Under the agreement, KORE Power will supply batteries according to NOMAD’s production schedule.
NOMAD signed a Master Equipment Supply and EPC (Engineer/Procure/Construct) Agreement with KORE Solutions (formerly Northern Reliability, Inc.), effective as of May 1, 2021 and amended effective April 11, 2022. The agreement is for the exclusive fabrication and supply of mobile energy storage systems, inclusive of associated KORE Power batteries, power docking stations, and related services. The purchase price for equipment and related services is KORE Solutions’ cost plus 25%.
NOMAD also entered into a management services and lease agreement with KORE Power, effective January 1, 2022, amended effective March 3, 2023, and amended effective October 1, 2023. Under the terms of the agreement, NOMAD will pay KORE Power for certain management services including accounting, secretarial, administration, marketing, and human resources, as well as the sub-lease of office space in Waterbury, Vermont. The agreement also specifies that KORE Power will be reimbursed for all third-party expenses reasonably incurred by KORE Power for the benefit of NOMAD in connection with the performance of these services. NOMAD will be invoiced by KORE Power monthly or quarterly, at KORE Power’s discretion.
On
October 1, 2023, the agreement was amended and restated, decreasing the payment to $
At
September 30, 2026 and December 31, 2025, the Company had outstanding payables due to KORE of approximately $
At
September 30, 2026 and December 31, 2025, the Company had accrued expenses due to KORE of approximately $
Securities Purchase Agreement with Aldersgate Capital Ltd. and BenEth Capital LLC
On June 7, 2026, in connection with the merger
described in Note 3, NOMAD entered into a Securities Purchase Agreement (the “SPA”) with Aldersgate Capital Ltd. (“Aldersgate”)
and BenEth Capital LLC (“BenEth”), among others. Under the SPA, NOMAD received aggregate cash proceeds of $
The warrants were classified as a derivative liability
(see Note 13). NOMAD recorded the warrant liability at its fair value of $
Following the merger, Aldersgate and BenEth each
hold
| 35 |
Note 18. Segment Information
Following
the July 1, 2026 acquisition, the Company evaluates its operations through
The Company’s chief operating decision maker (“CODM”), its Chief Executive Officer, reviews financial information presented on a subsidiary and company-wide basis and decides how to allocate resources based on net loss. Net loss is used for evaluating financial performance. The Company monitors budgeted versus actual results to assess performance and set management compensation.
Significant segment expenses include employee compensation, stock-based compensation, research and development costs, and consulting and outside provider costs. Other operating expenses include all remaining costs necessary to operate our business and primarily include advertising, corporate compliance, and overhead expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM:
Energy Storage
Schedule of Segment Expenses
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Employee compensation and benefits | $ | $ | $ | $ | ||||||||||||
| Stock-based compensation | ||||||||||||||||
| Facility costs | ||||||||||||||||
| Consulting and outside provider costs | ||||||||||||||||
| Transaction costs | - | - | ||||||||||||||
| Sales and marketing costs | ||||||||||||||||
| Depreciation expense | ||||||||||||||||
| Research and development expenses | ||||||||||||||||
| Other costs and expenses, net | ||||||||||||||||
| Total operating expenses | $ | $ | $ | $ | ||||||||||||
Oncology Development and Proton Therapy
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Employee compensation and benefits | $ | $ | - | $ | $ | - | ||||||||||
| Stock-based compensation | - | - | ||||||||||||||
| Facility costs | - | - | ||||||||||||||
| Consulting and outside provider costs | - | - | ||||||||||||||
| Transaction costs | ||||||||||||||||
| Research and development costs | - | - | ||||||||||||||
| Other costs and expenses, net | - | - | ||||||||||||||
| Total operating expenses | $ | $ | - | $ | $ | - | ||||||||||
Segment Reconciliations
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Employee compensation and benefits | $ | $ | $ | $ | ||||||||||||
| Stock based compensation | ||||||||||||||||
| Facility costs | ||||||||||||||||
| Consulting and outside provider costs | ||||||||||||||||
| Transaction costs | - | - | ||||||||||||||
| Sales and marketing costs | ||||||||||||||||
| Depreciation expense | ||||||||||||||||
| Research and development expenses | ||||||||||||||||
| Other costs and expenses, net | ||||||||||||||||
| Total operating expenses | $ | $ | $ | $ | ||||||||||||
| 36 |
19. Subsequent Events
Separation Agreement
On
November 6, 2026, the Company entered into a separation agreement with Geordan Pursglove, its former Chief Executive Officer, pursuant
to which his employment and service as an officer and director of the Company and its subsidiaries and affiliates terminated effective
that date. Under the agreement, the Company agreed to pay Mr. Pursglove $
Mr.
Pursglove agreed to provide transition services as an independent consultant through January 31, 2027, for up to 80 hours per month.
In consideration for these services, the Company agreed to grant him
Marketing Agreement
On
October 12, 2026, the Company entered into a marketing agreement with Quantum Ventures Inc. for a three-month term, subject to extension
by mutual agreement. Services include media creation, digital advertising, online awareness campaigns, content distribution, and strategic
business introductions. In consideration for these services, the Company agreed to pay a cash fee of $
Warrant Exercises
Subsequent
to September 30, 2026, the Company received cash proceeds of $
Consulting Agreement
On
November 3, 2026, the Company entered into a consulting agreement with Michael Hilmer, effective October 1, 2026, to provide strategic
and business advisory services, including budgeting, go-to-market planning, organizational readiness, financing discussions, and assistance
with data center transactions and rental strategies. The agreement provides for compensation of $
Other
On
October 3, 2026, the Company convened and adjourned a special meeting of stockholders to consider
| 37 |
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Forward-Looking Statements
This Quarterly Report on Form 10-Q of Nomad Power Solutions, Inc. (f/k/a Lixte Biotechnology Holdings, Inc.) (the “Company”) contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These might include statements regarding the Company’s financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future clinical trials and their timing and costs, product demand, supply, manufacturing costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as “intend”, “anticipate”, “believe”, “estimate”, “potential(ly)”, “continue”, “forecast”, “predict”, “plan”, “may”, “will”, “could”, “would”, “should”, “expect” or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. These forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected, anticipated or implied in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies or changes thereto, available cash, research and development results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included in Item 1 of this Quarterly Report on Form 10-Q, Exhibit 99.4 on Form 8-K/A (Amendment No.1) filed on September 17, 2026, and the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, including the section entitled “Item 1A. Risk Factors” filed on March 31, 2026. The Company does not intend to update or revise any forward-looking statements to reflect new information, future events, or otherwise.
Overview
On June 12, 2026, the Company entered into a definitive merger agreement to acquire NOMAD Transportable Power Systems, Inc. (“NOMAD”), a provider of deployable, utility-grade battery energy storage systems (“BESS”). Upon closing of the acquisition on July 1, 2026, the Company was renamed Nomad Power Solutions, Inc. effective July 3, 2026, and began trading on the Nasdaq Stock Market under a new ticker symbol on July 6, 2026.
The Company is an energy infrastructure equipment and services company focused on the design, manufacture, and deployment of transportable, utility-grade power and energy-storage systems. The Company’s systems are engineered to be delivered to a customer site, connected, and placed into operation in under one hour, without new grid interconnection, permitting, or civil works. The Company’s platform is intended to address circumstances in which available grid capacity is insufficient for a customer’s load, grid power is unavailable during planned maintenance or peak-hour restrictions, or demand charges and peak-hour rates render grid power uneconomical.
The Company conducts its transportable power business through its wholly-owned subsidiary, NOMAD Transportable Power Systems, Inc., and markets its systems under the Voyager platform.
The Company also maintains a life-sciences portfolio, including the protein phosphatase 2A inhibitor program (LB-100) advanced through LIXTE Biotechnology, and the electronically controlled proton therapy program (the LiGHT System) advanced through Liora Technologies. Through LIXTE Biotechnology, the Company advances LB-100, a small-molecule inhibitor of protein phosphatase 2A (PP2A) being evaluated in clinical trials in combination with immunotherapy and chemotherapy across multiple cancer indications. Through Liora Technologies, the Company advances the LiGHT System (Linac for Image Guided Hadron Therapy), an electronically controlled proton-therapy platform. The Company has indicated an intent to evaluate a disposition of its legacy life-sciences portfolio as it focuses on its transportable power business; the status and terms of any such disposition have not yet been determined.
| 38 |
Description of Business
Electricity users increasingly encounter circumstances in which the grid cannot deliver sufficient power at the time, location, or price required. Utilities may be unable to deliver the load a customer needs, or interconnection of new capacity may take years; planned maintenance, curtailment, or peak-hour restrictions may interrupt supply; and demand charges and peak-hour rates may make grid power uneconomical. The Company’s systems are intended to address each of these circumstances by delivering utility-grade power to the customer’s site on a rapidly deployable, relocatable basis.
Because the Company’s systems are delivered, connected, and placed into service without new permanent grid infrastructure, the Company markets them as a means of adding power capacity, bridging supply during outages and restricted windows, and shifting consumption from peak to off-peak periods to reduce demand charges. The Company’s systems have been deployed and operated on live utility grids.
The Voyager Platform
The Company’s principal product line is the Voyager platform, a family of containerized, transportable power and energy-storage systems built on a common architecture and offered in three configurations. The Voyager platform is a mobile battery energy storage system (MBESS) designed to be energy-agnostic, i.e., it can charge from any power source (grid power, solar, wind, etc.), and be mobilized to various locations where power is needed. Each system is trailer-mounted in a 20-foot form factor, operates at 480 volts, and is designed to deploy in under one hour. The three configurations are set forth below:
| Model | Continuous Power | Energy Storage | Deployment | |||
| Voyager Eagle | 999 kW | 2.0 MWh | Under 1 hour | |||
| Voyager Falcon | 500 kW | 2.0 MWh | Under 1 hour | |||
| Voyager Hawk | 500 kW | 1.0 MWh | Under 1 hour |
The original and still operating fleet of NOMAD units utilizes NMC batteries. All 2026 models ordered and to be delivered use lithium iron phosphate (LFP) battery chemistry rated for a cycle life exceeding 6,000 cycles, with integrated fire safety. The continuous power of the systems details the maximum amount of power that can be charged/discharged and the energy storage numbers are the maximum amount of power the system can hold at any given time. The systems are designed to be relocatable across territories, sectors, and seasons.
We expect that our existing cash resources and customer revenues will provide sufficient working capital resources to fund our operations, including the development of Voyager and LFP battery platform, through December 31, 2026. The Company estimates that it will need to raise additional capital to fund its operations by December 31, 2026, to be able to proactively manage its current business plan during 2027. In addition, our operating plan might change as a result of many factors currently unknown to us, including possible additional company acquisitions, production capacity, raw material costs, advanced systems and technology, and we might need additional funds sooner than planned. The Company is considering various strategies and alternatives to obtain the required additional capital.
We expect to expend substantial resources for the foreseeable future to continue the development of Voyager, LFP battery platform and new product offerings. These expenditures will include costs associated with product development, supply chain, marketing, increased payroll, obtaining regulatory approvals and manufacturing of products.
Budgets and future capital requirements depend on many factors, including:
| ● | our operating expenses | |
| ● | costs of raw materials. | |
| ● | supply shortages | |
| ● | production capacity | |
| ● | enhancing research and development | |
| ● | third parties’ failure to meet contractual commitments | |
| ● | economic downturn |
| 39 |
Additional funds might not be available when we need them, on terms acceptable to us, or at all. We have no committed source of additional capital. If adequate funds are not available to us on a timely basis, we might not be able to continue as a going concern, or we might be required to delay, limit, reduce, or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize our lead product candidate and new product offerings.
The Company is currently conducting early-stage clinical trials involving LB-100. These activities require substantial expenditures for research, development, regulatory compliance and clinical activities. The Company does not expect its life-sciences programs to generate sustainable operating revenue for several years, if ever.
For the nine months ended September 30, 2026, the Company incurred a net loss of $167,314 and used $8,297 of cash in operating activities. As of September 30, 2026, the Company had cash of $5,649. The Company has incurred recurring losses and negative operating cash flows as it advances its development programs.
Liquidity and Going Concern
Based on the fact that the Company has no significant recurring source of revenue, has used cash in operating activities since inception, has anticipated expenditures, and the need for additional capital, management concluded that substantial doubt exists regarding the Company’s ability to continue as a going concern for at least 12 months following the date on which the condensed consolidated financial statements are issued.
The report of the Company’s independent registered public accounting firm on the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 also included an explanatory paragraph regarding substantial doubt about the Company’s ability to continue as a going concern.
The condensed consolidated financial statements have been prepared on a going-concern basis and do not include any adjustments that could result from the outcome of this uncertainty.
Management continues to evaluate and pursue financing alternatives, including equity and debt financings and potential strategic transactions. There can be no assurance that additional capital will be available when needed, on acceptable terms or in amounts sufficient to fund the Company’s operations.
If the Company cannot obtain sufficient additional funding, it may be required to delay, reduce, or discontinue one or more clinical-development programs, curtail expenditures related to the LiGHT system, sell assets, pursue other strategic alternatives, or cease operations.
Recent Accounting Pronouncements
Information regarding recently issued accounting pronouncements is included in Note 2 to the condensed consolidated financial statements for the three and nine months ended September 30, 2026 and 2025 included elsewhere in this Quarterly Report.
Critical Accounting Policies and Estimates
The Company’s significant accounting policies are described in Note 2 to the condensed consolidated financial statements for the three and nine months ended September 30, 2026 and 2025 included elsewhere in this Quarterly Report. These policies, together with the estimates and assumptions used in their application, are important to an understanding of the Company’s financial condition and results of operations.
Management evaluates its accounting estimates and assumptions on an ongoing basis using historical experience, current conditions and other factors it considers relevant. Actual results may differ from these estimates.
There have been no material changes to the Company’s critical accounting policies and estimates from those disclosed in its most recent Annual Report on Form 10-K.
| 40 |
Specific Risks Associated with the Company’s Business Activities
Serious Adverse Events
LB-100 is being evaluated in multiple clinical trials. One or more of these trials could be placed on hold or terminated by an institutional review board, the U.S. Food and Drug Administration, the European Medicines Agency or another regulatory authority as a result of a serious adverse event (“SAE”) involving LB-100 or another therapy administered in combination with LB-100.
Potential SAEs could include unexpected severe side effects, treatment-related deaths or long-term health complications. A patient may also experience a dose-limiting toxicity (“DLT”). Under applicable clinical-trial protocols, the occurrence of multiple DLTs at a particular dose level may result in that dose being considered unsafe and may require subsequent patients to be treated at a lower dose level previously determined to be tolerable.
If an SAE or a pattern of SAEs occurs during a clinical trial involving LB-100, regulatory authorities or institutional review boards may require the Company or the trial sponsor to suspend enrollment or dosing, modify the trial protocol, conduct additional studies or terminate the trial. Any such action could delay or prevent further development of LB-100, increase the Company’s development costs and adversely affect its ability to obtain regulatory approval.
An SAE or related clinical hold could also adversely affect the Company’s reputation among patients, investigators, medical institutions and investors; impede patient recruitment; and impair the Company’s ability to obtain financing or enter into strategic arrangements. There can be no assurance that additional SAEs will not occur or that any clinical hold will be lifted in a timely manner or at all.
The principal investigator of the colorectal cancer study evaluating LB-100 in combination with atezolizumab, a Roche PD-L1 inhibitor, is investigating two SAEs observed in the trial, which commenced in August 2024. The Institutional Review Board (the “IRB”) of the Netherlands Cancer Institute (“NKI”) placed the study on hold.
One patient experienced dyspnea associated with lung toxicity that was considered possibly or probably related to the combination of LB-100 and atezolizumab. That patient subsequently died from complications associated with lung metastases and dyspnea. A second patient experienced fever and aphasia that were considered possibly or probably related to the drug combination. The second patient fully recovered following supportive treatment.
The NKI IRB requested additional information from the principal investigator regarding whether the adverse events may have been caused by the combination of LB-100 and atezolizumab and the potential mechanism of action of the combination. The principal investigator submitted a response describing the safety experience with LB-100 administered alone and in combination with other cancer therapies, including doxorubicin and dostarlimab.
The adverse events reported in the colorectal cancer trial had not been observed in other patients treated with LB-100, either alone or in combination with other cancer therapies. As of early July 2025, the Company had been informed that approximately 82 patients had received or were receiving experimental treatment involving LB-100.
In May 2025, the Company updated the safety information relating to LB-100 and distributed Version 5.0 of the Investigator’s Brochure to investigators participating in the Company’s ongoing clinical trials. The Investigator’s Brochure includes relevant preclinical, clinical and pharmacological information concerning the administration of LB-100 to humans. The investigators conducting the colorectal cancer study, NCT06012734, submitted a detailed response to the NKI IRB that included the updated Investigator’s Brochure. Since January 2026, the trial has been actively recruiting patients.
External Risks Associated with the Company’s Business Activities
Public Health Risks
The COVID-19 pandemic resulted in disruptions to global economic and business activity beginning in 2020. Although the effects of the pandemic have substantially subsided, a resurgence of COVID-19 or the emergence of another public-health emergency could disrupt the Company’s clinical-development activities, relationships with vendors and clinical sites, access to capital and general business operations. The extent of any future impact cannot be predicted.
| 41 |
Inflation and Interest-Rate Risk
The Company does not believe that inflation or changes in interest rates have had a material direct effect on its operations to date, other than through their broader effects on the economy and capital markets. However, inflationary pressures could increase the costs of clinical trials, contract research, manufacturing, personnel and other operating activities.
Higher interest rates could also increase borrowing costs and adversely affect the availability and terms of financing.
Supply-Chain Risk
The Company does not currently anticipate that supply-chain constraints will materially affect its ongoing clinical trials. However, future disruptions could delay the manufacturing, testing, storage or delivery of LB-100 or other materials required for the Company’s development programs.
Economic and Capital-Market Risk
A recession or deterioration in economic conditions could adversely affect the general business environment and capital markets. Such conditions could make it more difficult or costly for the Company to obtain financing and could adversely affect the market price of its common stock.
Geopolitical Risk
Military conflicts, trade restrictions and other geopolitical developments could disrupt supply chains and adversely affect the availability and cost of materials and services required for the Company’s research, clinical-development, testing and manufacturing activities. Such developments could also delay clinical trials or other development activities.
Geopolitical uncertainty may also increase volatility in global financial markets, adversely affect investor confidence and market sentiment, and limit the Company’s access to capital. These risks are outside the Company’s control, and their effect on the Company’s business, financial condition and results of operations may differ materially from management’s current expectations.
Cybersecurity Risk
The Company has established policies and processes designed to assess, identify and manage material risks arising from cybersecurity threats and has integrated these processes into its overall risk-management framework.
The Company periodically assesses cybersecurity risks, including risks of unauthorized access to or activity involving its information and email systems that could adversely affect the confidentiality, integrity or availability of those systems or the information maintained in them. The Company also performs assessments when material changes in its business practices could affect information systems that may be vulnerable to cybersecurity threats.
These assessments include consideration of reasonably foreseeable internal and external risks, the likelihood and potential impact of such risks, and the adequacy of the Company’s policies, procedures, systems and safeguards. The Company has not identified any cybersecurity incident that has materially impaired its operations or financial condition.
The Company continues to monitor these matters and may adjust its business and financing plans as additional information becomes available.
| 42 |
Results of Operations
The Company’s condensed consolidated statements of operations as discussed herein are presented below.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except share and per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Sales | $ | 472 | $ | 652 | $ | 1,093 | $ | 7,261 | ||||||||
| Cost of goods sold | 470 | 539 | 1,015 | 6,783 | ||||||||||||
| Gross profit | 2 | 113 | 78 | 478 | ||||||||||||
| Costs and expenses: | ||||||||||||||||
| General and administrative costs | 9,201 | 1,174 | 10,845 | 3,674 | ||||||||||||
| Research and development costs | 473 | 31 | 832 | 1,044 | ||||||||||||
| Transaction costs | 5,413 | - | 6,434 | - | ||||||||||||
| Total costs and expenses | 15,087 | 1,205 | 18,111 | 4,718 | ||||||||||||
| Loss from operations | (15,085 | ) | (1,092 | ) | (18,033 | ) | (4,240 | ) | ||||||||
| Other income (expenses): | ||||||||||||||||
| Interest income | 8 | 1 | 8 | 1 | ||||||||||||
| Interest expense | (103 | ) | (352 | ) | (832 | ) | (1,292 | ) | ||||||||
| Loss on debt extinguishment | (3 | ) | - | (1,355 | ) | - | ||||||||||
| Loss (gain) on issuance of warrant liability | 1,500 | - | (123,941 | ) | - | |||||||||||
| Change in fair value of warrant liability | - | - | (23,161 | ) | - | |||||||||||
| Other expense | - | - | - | - | ||||||||||||
| Net loss | (13,683 | ) | (1,443 | ) | (167,314 | ) | (5,531 | ) | ||||||||
| Non-controlling interest | 47 | - | 47 | - | ||||||||||||
| Net loss attributable to common stockholders | $ | (13,636 | ) | $ | (1,443 | ) | $ | (167,267 | ) | $ | (5,531 | ) | ||||
Three Months Ended September 30, 2026 and 2025
Sales. For the three months ended September 30, 2026, the Company had sales of $472, compared with $652 for the three months ended September 30, 2025. The decrease in sales was related to the transition from our historical NMC battery platform to the new LFP battery platform. The company accelerated the switchover to the LFP battery platform in response to market shifts in LFP battery supply and demand.
Cost of Goods Sold. For the three months ended September 30, 2026, cost of goods sold was $470, compared with $539 for the three months ended September 30, 2025. The decrease in cost of goods sold was due to our decreased sales.
General and Administrative Costs. For the three months ended September 30, 2026, general and administrative costs were $9,201, compared with $1,174 for the three months ended September 30, 2025. General and administrative costs increased due to higher stock-based compensation expense of $6,643, higher consulting and professional fees of $735, and higher other general and administrative expenses of $649 to support our operations.
Research and Development Costs. For the three months ended September 30, 2026, research and development costs were $473, compared to $31 for the three months ended September 30, 2025. Research and development costs increased due to our shift from NMC to LFP Battery platform technology.
| 43 |
Transaction Costs. For the three months ended September 30, 2026, transaction costs of $5,413 were related to our reverse acquisition (see Note 3 of the accompanying financial statements). No comparable expense was incurred in the prior year period.
Other Income (Expenses). For the three months ended September 30, 2026, the Company had interest income of $8, interest expense of $103, and a loss on debt extinguishment of $3. In addition, the Company recorded a gain on issuance of warrant liability of $1,500, which did not occur in the prior year period. For the three months ended September 30, 2025, the Company had interest income of $1 and interest expense of $352. Interest expense decreased because our debt balance decreased.
Net Loss. For the three months ended September 30, 2026, the Company incurred a net loss of $13,683, as compared to a net loss of $1,443 for the three months ended September 30, 2025. The net loss increased primarily because of higher stock-based compensation expenses and higher operating expenses, as discussed above.
Nine Months Ended September 30, 2026 and 2025
Sales. For the nine months ended September 30, 2026, the Company had sales of $1,093, compared with $7,261 for the nine months ended September 30, 2025. The decrease in sales was related to the transition from our historical NMC battery platform to the new LFP battery platform. The company accelerated the switchover to the LFP battery platform in response to market shifts in LFP battery supply and demand.
Cost of Goods Sold. For the nine months ended September 30, 2026, cost of goods sold was $1,015, compared with $6,783 for the nine months ended September 30, 2025. The decrease in cost of goods sold was due to our decreased sales.
General and Administrative Costs. For the nine months ended September 30, 2026, general and administrative costs were $10,845, compared with $3,674 for the nine months ended September 30, 2025. General and administrative costs increased due to higher stock-based compensation expense of $6,567 and higher consulting and professional fees of $629, offset by a $25 decrease in other general and administrative expenses to support our operations.
Transaction Costs. For the nine months ended September 30, 2026, transaction costs of $6,434 were related to our reverse acquisition (see Note 3 of the accompanying financial statements). No comparable expense was incurred in the prior year period.
Research and Development Costs. For the nine months ended September 30, 2026, research and development costs were $832, compared to $1,044 for the nine months ended September 30, 2025. Research and development costs decreased due to our shift from NMC to LFP Battery platform technology.
Other Income (Expenses). For the nine months ended September 30, 2026, the Company had interest income of $8, interest expense of $832, a $1,355 loss on debt extinguishment, a $123,941 loss on issuance of warrant liability, and a $23,161 loss on the change in fair value of warrant liability. The loss on debt extinguishment and warrant liability activity did not occur in the prior year period. For the nine months ended September 30, 2025, the Company had interest income of $1 and interest expense of $1,292. Interest expense decreased because our debt balance decreased.
Net Loss. For the nine months ended September 30, 2026, the Company incurred a net loss of $167,314, as compared to a net loss of $5,531 for the nine months ended September 30, 2025. The net loss increased primarily because of higher stock-based compensation expense and higher operating expenses, as discussed above.
Deferred Revenue. Deferred revenue, which represents payments received from customers for systems not yet delivered, was $9,644 at September 30, 2026, compared with $8,173 at December 31, 2025. Deferred revenue relates to orders within the Company’s previously announced backlog of more than $30 million in customer orders. Deferred revenue and the balance of the backlog will be recognized as revenue as systems are delivered.
Liquidity and Capital Resources – September 30, 2026
The Company’s condensed consolidated statements of cash flows as discussed herein are as follows:
Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| (Amounts in thousands) | ||||||||
| Net cash provided by (used in) operating activities | $ | (8,297 | ) | $ | 726 | |||
| Net cash provided by (used in) investing activities | 12,630 | (53 | ) | |||||
| Net cash provided by (used in) financing activities | 1,160 | (697 | ) | |||||
| Net increase (decrease) in cash | $ | 5,493 | $ | (24 | ) | |||
| 44 |
Operating Activities
Cash provided by or used in operating activities primarily consists of net loss adjusted for certain non-cash items, including loss on issuance of warrant liability, the change in fair value of warrant liability, loss on debt extinguishment, and the fair value of vested stock options, restricted stock units, and common shares issued for employee compensation and to outside service providers, and the effect of changes in working capital and other activities.
Cash used in operating activities for the nine months ended September 30, 2026 was $8,297 and consisted of our net loss of $167,267, adjusted for non-cash items such as the loss on issuance of warrant liability of $123,941, the loss on change in fair value of our warrant liability of $23,161, the fair value of vested restricted stock units of $6,875, and the fair value of common stock issued for services of $5,077, and routine changes in working capital and other activities.
Cash provided by operating activities for the nine months ended September 30, 2025 was $726 and consisted of our net loss of $5,531, adjusted for non-cash items such as the fair value of vested restricted stock units of $264, the amortization of debt discount of $235, and routine changes in working capital and other activities.
Investing Activities
Cash provided by investing activities for the nine months ended September 30, 2026 was $12,630, which was from $12,670 net cash received from our reverse acquisition, offset by $25 for intangible asset costs and $11 for fixed asset purchases and $4 of capitalized LiGHT system costs.
Cash used in investing activities for the nine months ended September 30, 2025 was $53 for intangible asset costs.
Financing Activities
Cash provided by financing activities for the nine months ended September 30, 2026 was $1,160, which was from $1,500 of cash proceeds on the issuance of liability-classified warrants, cash proceeds of $74 on the exercise of stock options, cash proceeds of $365 on the exercise of warrants, debt proceeds of $12,382, offset by $4,272 used to purchase fundamental transaction warrants, debt repayment of $8,099, and shareholder distributions of $790.
Cash used in financing activities for the nine months ended September 30, 2025 was $697, which was from debt proceeds of $555 offset by debt repayment of $1,252.
Going Concern
For the nine months ended September 30, 2026, the Company incurred a net loss of $167,314 and used cash in operations of $8,297. As of September 30, 2026, the Company had $5,649 in cash available to fund its operations. The Company has incurred negative operating cash flows as it advances its development programs. As a result, management has concluded that there is substantial doubt regarding the Company’s ability to continue as a going concern for a period of at least 12 months beyond the filing of this quarterly report. In addition, the Company’s independent registered public accounting firm, in their audit report on the financial statements of NOMAD for the year ended December 31, 2025, included an explanatory paragraph regarding substantial doubt about NOMAD’s ability to continue as a going concern.
Goodwill
Goodwill of $94.3 million arose from the acquisition of Lixte and represented approximately 77% of the Company’s total assets at September 30, 2026. The Company has two reporting units. It tests goodwill for impairment annually as of December 31, or more often if events or changes in circumstances indicate that the fair value of the reporting unit may be below its carrying amount. Because the Company’s common stock is publicly traded, management considers the Company’s market capitalization to be a key indicator of the fair value of the reporting unit.
During the three months ended September 30, 2026, the Company’s stock price declined. Based on the September 30, 2026 closing price, the market value of the Company’s outstanding common stock was below the carrying amount of its stockholders’ equity of $100 million. Including the 50,366,070 shares of common stock issuable on conversion of the Series D Convertible Preferred Stock, management estimated the market value of the Company’s equity at September 30, 2026, would exceed the carrying amount of stockholders’ equity. After assessing these factors, management concluded that a quantitative impairment test was not required at September 30, 2026, and no impairment of goodwill was recognized.
A further decline in the Company’s stock price, a failure to obtain the approvals required for conversion of the Series D Convertible Preferred Stock, or a failure to achieve projected results could indicate that the fair value of a reporting unit is below its carrying amount. In that event, the Company may be required to recognize a goodwill impairment charge, which could be material, in a future period, including in connection with its annual impairment test as of December 31, 2026
Trends, Events and Uncertainties
Research and development of new pharmaceutical compounds is, by its nature, unpredictable. Although the Company undertakes research and development efforts with commercially reasonable diligence, there can be no assurance that the Company’s cash position will be sufficient to enable it to develop any pharmaceutical compound to the extent needed to create future sales to sustain operations as contemplated herein.
There can be no assurance that the Company’s pharmaceutical compound will obtain the regulatory approvals and market acceptance to achieve sustainable revenues sufficient to support the Company’s operations. Even if the Company is able to generate revenues, there can be no assurance that the Company will be able to achieve operating profitability or positive operating cash flows. There can be no assurance that the Company will be able to secure additional financing, to the extent required, on acceptable terms or at all. If cash resources are insufficient to satisfy the Company’s ongoing cash requirements, the Company would be required to reduce or discontinue its research and development programs, or attempt to obtain funds, if available, through strategic alliances, joint ventures or other transaction structures that could require the Company to relinquish rights to and/or control of LB-100, or to discontinue operations entirely.
Other than as discussed above, the Company is not currently aware of any trends, events or uncertainties that are likely to have a material effect on its financial condition in the near term, although it is possible that new trends or events may develop in the future that could have a material effect on the Company’s financial condition.
| 45 |
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK
Not applicable.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Management, with the participation of the Company’s principal executive officer and principal financial officer, evaluated the effectiveness of the Company’s disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, as of September 30, 2026. Disclosure controls and procedures are designed to ensure that information required to be disclosed in the Company’s reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to management, including the Company’s principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.
Based on this evaluation, the Company’s principal executive officer and principal financial officer concluded that the Company’s disclosure controls and procedures were not effective as of September 30, 2026 because of the material weaknesses in internal control over financial reporting described below.
Material Weaknesses in Internal Control Over Financial Reporting
A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.
Management identified the following material weaknesses in the Company’s internal control over financial reporting:
The following three deficiencies are related to the Company’s subsidiary, Nomad Transportable Power Systems, Inc. (“NOMAD”). As such, they were never previously disclosed in any of the former Lixte Biotechnology Holdings filings. They were identified in past annual audits and interim reviews of the subsidiary.
| 1. | Segregation of duties. NOMAD did not design and maintain effective controls over segregation of duties, including controls over the preparation, review and approval of journal entries and account reconciliations. This material weakness was initially identified during a past audit of NOMAD’s financial statements and persisted through September 30, 2026, due to employee turnover and the limited size of NOMAD’s accounting and finance department. | |
| 2. | Inventory controls. NOMAD did not design and maintain effective controls to ensure accurate physical inventory counts, consistent tracking of inventory movements and complete and accurate reconciliation of inventory to the accounting records. These limitations could result in material misstatements of inventory and related financial statement accounts. This material weakness was identified in connection with past audits of NOMAD’s financial statements and remained unremediated as of September 30, 2026. | |
| 3. | Accounting for equity and warrant instruments. NOMAD did not design and maintain effective controls over the technical accounting evaluation and recording of equity and warrant instruments, including the determination of whether such instruments should be classified as liabilities or equity. This material weakness resulted in errors in the classification and presentation of certain instruments identified during the review of NOMAD’s interim financial statements for the period ended June 30, 2026. Although these transactions are complex and were infrequent for NOMAD, the magnitude of the errors and the potential for future material misstatements demonstrated a deficiency in controls over these transactions. This material weakness remained unremediated as of September 30, 2026. |
The following deficiency was identified by management during the quarter ended September 30, 2026:
| 4. | Payroll taxes associated with equity compensation. The Company did not design and maintain effective controls to ensure the timely collection and remittance of employee payroll taxes and payment of employer payroll taxes associated with the vesting of restricted stock units. As a result, the Company did not timely collect and remit the applicable employee payroll taxes or pay the related employer payroll taxes for certain transactions in 2026. Although the related payroll tax liabilities were properly recorded as of September 30, 2026, these amounts remained unpaid at that date. This control deficiency also created a risk that related payroll tax obligations, employee receivables, and any associated penalties and interest might not be completely and accurately accounted for and disclosed on a timely basis. Management determined that these deficiencies constituted a material weakness in internal control over financial reporting. |
Remediation of Material Weaknesses
In order to remediate these material weaknesses, we will change certain control activities over financial reporting to include, but not limited to, the following: (i) evaluating and implementing enhanced process controls around user access management and segregation of duties, (ii) enhancing the level of evidence maintained in management review controls and (iii) enhancing the design of existing controls and implementing new controls over the accounting, processing, and recording of payroll taxes associated with equity compensation.
Management continues to implement remediation to address the material weaknesses described above, including: (i) enhancing financial close and reporting processes by implementing additional levels of review over manual journal entries, formalizing account reconciliation procedures, and requiring documented supervisory approval of all non-routine and significant adjustments; (ii) strengthening the finance and internal control environment by augmenting finance personnel and reassigning responsibilities to improve segregation of duties, engaging qualified third-party professionals to assist with internal audit-type procedures and ongoing monitoring where internal resources are limited, and completing and maintaining comprehensive documentation of key accounting policies, procedures, and internal controls; and (iii) enhancing the design of existing controls and implementing new controls over the accounting, processing, and recording of payroll taxes associated with equity compensation.
Management is implementing improvements to the Company’s inventory controls that include: (i) frequent, scheduled counts of specific SKU subsets to catch and fix discrepancies early; (ii) separating the staff who physically count the inventory from the personnel who manage the ledger records to prevent bias or concealed shrinkage; (iii) enforcing strict adjustment controls by requiring mandatory documentation for every inventory adjustment
| ● | To address the material weaknesses related to segregation of duties and accounting for equity and warrant instruments, management is implementing the following measures: (i) ensure no single person controls authorization, custody, record-keeping, and reconciliation for the same transaction; (ii) strengthening the finance and internal control environment by augmenting finance personnel and reassigning responsibilities to improve segregation of duties; (iii) an independent second person reviews bank statements, vendor lists, and payroll changes; (iv) the person who prepares a manual journal entry will mandate a secondary review by a supervisor or controller;(v) a monthly independent review of all manual, high-risk, or non-standard journal entries; (vi) implementing additional controls over the authorization and issuance of equity securities, including requiring documented legal and accounting review, prior to any issuance of shares upon the exercise or conversion of warrants or other convertible instruments, to confirm that the instrument is then exercisable or convertible in accordance with its terms and that all conditions to exercisability — including any required stockholder approval, registration, and legending requirements — have been satisfied; and (vii) improving coordination among the Company’s finance function, legal advisors, placement agents, and transfer agent in connection with financing transactions. |
The material weaknesses related to segregation of duties, inventory controls, and accounting for equity and warrant instruments remained unremediated as of September 30, 2026. These material weaknesses will not be considered remediated until the applicable controls have been implemented and have operated for a sufficient period for management to conclude, through testing, that they are operating effectively.
To address the payroll tax material weakness, the Company: (i) established procedures to communicate equity award vesting events to payroll/accounting personnel; (ii) created a mandatory prevesting checklist that requires the equity administrator to send a vesting schedule report to accounting at least 5 days before any restricted stock vest; (iii) accounting to calculate the estimated employer and employee payroll taxes based on the vesting schedule and configure an off-cycle payroll run to process on the vesting date; and (vi) a month-end and quarter-end review of RSU’s granted.
Based on its evaluation and testing of the design and operating effectiveness of the implemented controls, management concluded that the material weakness related to payroll taxes associated with equity compensation was remediated as of November 11, 2026. The controls operated for a sufficient period to support management’s conclusion that they were operating effectively
The remediation of the payroll tax material weakness does not resolve the Company’s other material weaknesses or change management’s conclusion that disclosure controls and procedures were not effective as of September 30, 2026.
Changes in Internal Control Over Financial Reporting
Other than the changes described above, there were no changes in the Company’s internal control over financial reporting during the three months ended September 30, 2026 that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
| 46 |
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
The Company is not currently subject to any pending or threatened legal actions or claims.
ITEM 1A. RISK FACTORS
Not required for smaller reporting companies.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
Not applicable.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
During
the three months ended September 30, 2026, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company
On November 13, 2026, the Board of Directors appointed Michael Hilmer Chairman of the Board and Interim Chief Executive Officer, and appointed John Travaglini Chief Executive Officer of the Company’s subsidiary, NOMAD Transportable Power Systems, Inc. Mr. Hilmer and Mr. Travaglini continue to be compensated under their existing consulting agreements pending Board approval of their compensation.
Michael A. Hilmer, age 58, is a Toronto-based entrepreneur, investor and corporate director with three decades of experience founding, financing, scaling and overseeing businesses across Canada and the United States. He has chaired several boards and currently serves as a director of both public and private companies, including other Nasdaq-listed issuers. Over his career, Mr. Hilmer has built and exited multiple companies in financial technology, consumer lending and enterprise software, overseen more than $1.3 billion in equity and debt underwriting, and completed more than a dozen acquisitions and other transactions. He brings deep experience in capital markets, transaction structuring, and litigation-sensitive and special situations, along with a track record of leading businesses through periods of rapid growth. Mr. Hilmer works collaboratively with management teams, combining an entrepreneurial perspective with a disciplined approach to balancing risk and reward.
There are no family relationships between Mr. Hilmer and any director or executive officer of the Company. Other than his consulting agreement described in Note 19 to the condensed consolidated financial statements, Mr. Hilmer has no direct or indirect material interest in any transaction required to be disclosed under Item 404(a) of Regulation S-K.
John Travaglini, age 65, has served as a director of the Company since the closing of the merger on July 1, 2026, and as Chief Executive Officer of NOMAD Transportable Power Systems, Inc. since November 13, 2026. Mr. Travaglini has more than 20 years of experience in mergers and acquisitions and capital raising. He is the founder of 4Front Capital Partners and built a systems integration business to more than $55 million in [revenue].
There are no family relationships between Mr. Travaglini and any director or executive officer of the Company. Other than his consulting agreement with the Company, Mr. Travaglini has no direct or indirect material interest in any transaction required to be disclosed under Item 404(a) of Regulation S-K.
| 47 |
ITEM 6. EXHIBITS
The following documents are filed as part of this report:
| Exhibit Number | Description of Document | |
| 2.1 | Merger Agreement, dated as of June 11, 2026, by and among Lixte Biotechnology Holdings, Inc., NBD Merger Sub, Inc., and NOMAD Transportable Power Systems, Inc., filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on June 16, 2026, and incorporated herein by reference. | |
| 2.2 | Amendment No. 1 to Merger Agreement, dated as of June 30, 2026, by and among Lixte Biotechnology Holdings, Inc., NBD Merger Sub, Inc., and NOMAD Transportable Power Systems, Inc., filed as Exhibit 2.2 on Form 8-K, as filed with the Securities and Exchange Commission on July 2, 2026, and incorporated herein by reference. | |
| 3.1 | Certificate of Amendment to the Certificate of Incorporation of Lixte Biotechnology Holdings, Inc., filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on June 6, 2023 and incorporated herein by reference. | |
| 3.2 | Amended and Restated Bylaws, filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 10, 2022 and incorporated herein by reference. | |
| 3.3 | Certificate of Amendment of Certificate of Incorporation of Lixte Biotechnology Holdings, Inc., filed as Exhibit 3.1 on Form 8-K, as filed with the Securities and Exchange Commission on July 2, 2026, and incorporated herein by reference. | |
| 3.4 | Amendment to Amended and Restated Bylaws filed as Exhibit 3.2 on Form 8-K, as filed with the Securities and Exchange Commission on July 2, 2026, and incorporated herein by reference. | |
| 3.5 | Certificate of Designations of Preferences, Rights and Limitations of Series D Non-Voting Convertible Preferred Stock, filed as Exhibit 3.3 on Form 8-K, as filed with the Securities and Exchange Commission on July 2, 2026, and incorporated herein by reference. | |
| 4.1 | Form of Pre-Funded Warrant to Purchase Common Stock, dated as of July 3, 2025, filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on July 8, 2025 and incorporated herein by reference. | |
| 4.2 | Note dated September 28, 2026, filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on September 30, 2026, and incorporated herein by reference. | |
| 10.1 | Form of Securities Purchase Agreement, dated as of July 3, 2025, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on July 8, 2025 and incorporated herein by reference. | |
| 10.2 | Registration Rights Agreement, filed as Exhibit 10.1 on Form 8-K, as filed with the Securities and Exchange Commission on July 2, 2026, and incorporated herein by reference. | |
| 10.3 | Stockholder Support Agreement, filed as Exhibit 10.2 on Form 8-K, as filed with the Securities and Exchange Commission on July 2, 2026, and incorporated herein by reference. | |
| 10.4 | Form of Indemnification Agreement, filed as Exhibit 10.3 on Form 8-K, as filed with the Securities and Exchange Commission on July 2, 2026, and incorporated herein by reference. | |
| 10.5 | Separation Agreement between Geordan Pursglove and Nomad Power Solutions, Inc., dated November 9, 2026., filed as Exhibit 10.1 on Form 8-K, as filed with the Securities and Exchange Commission on November 10, 2026, and incorporated herein by reference. | |
| 10.6 | Consulting Agreement between Michael Hilmer and Nomad Power Solutions, Inc. dated November 9, 2026, filed as Exhibit 10.2 on Form 8-K, as filed with the Securities and Exchange Commission on November 10, 2026, and incorporated herein by reference. | |
| 10.7 | Note Purchase Agreement dated September 28, 2026, filed as Exhibit 10.1 on Form 8-K, as filed with the Securities and Exchange Commission on September 30, 2026, and incorporated herein by reference | |
| 10.8 | Security Agreement dated September 28, 2026, filed as Exhibit 10.2 on Form 8-K, as filed with the Securities and Exchange Commission on September 30, 2026, and incorporated herein by reference. | |
| 10.9 | Guaranty dated September 28, 2026, filed as Exhibit 10.3 on Form 8-K, as filed with the Securities and Exchange Commission on September 30, 2026, and incorporated herein by reference. | |
| 31.1* | Officer’s Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
| 31.2* | Officer’s Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
| 32.1* | Officer’s Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| 32.2* | Officer’s Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| 101.INS | Inline XBRL Instance Document (does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL document and included in Exhibit 101.INS) |
* Filed herewith.
| 48 |
SIGNATURES
In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| NOMAD POWER SOLUTIONS, INC. | ||
| (Registrant) | ||
| Date: November 16, 2026 | By: | /s/ MICHAEL HILMER |
| Michael Hilmer | ||
| Chairman and Interim Chief Executive Officer | ||
| (Principal Executive Officer) | ||
| Date: November 16, 2026 | By: | /s/ PETER STAZZONE |
| Peter Stazzone | ||
| Chief Financial Officer | ||
| (Principal Financial and Accounting Officer) | ||
| 49 |